Kava

'''Kava''' (''Piper methysticum'' G.Forst.) is a plant preparation from the Piperaceae family consumed as an aqueous root beverage across the Pacific Islands for its [[substance_class:psychoactive/anxiolytic]] and sedative properties. Its pharmacology is driven by kavalactones — six substituted α-pyrones accounting for approximately 96% of the root's lipid resin{{cite|pubmed=12383029|anchor=9f1ce46b}}{{cite|doi=10.3390/nu12103044|anchor=177df739}}. Duration ranges from 2–4 hours for traditional aqueous beverages to 4–8 hours for standardized pharmaceutical extracts. Georg Forster first described ''P. methysticum'' in 1786 from specimens collected during Captain Cook's second Pacific voyage{{cite|name=gbif-piper-methysticum|type=web|year=2024|title=Piper methysticum G.Forst. taxonomy and botanical identity|anchor=91ae85de}}. Pacific Island cultures have consumed kava in social, ceremonial, and medicinal contexts for at least 3,000 years{{cite|doi=10.3390/nu12103044|anchor=5886dd6d}}. Clinical research has confirmed anxiolytic [[glossary:efficacy]] in multiple [[glossary:randomized-controlled-trial|randomized controlled trials]] and Cochrane reviews{{cite|pubmed=12076477|anchor=4657c886}}{{cite|doi=10.1177/0004867419891246|anchor=751c16cb}}. A complex regulatory arc — European bans following [[glossary:hepatotoxicity]] [[glossary:case-report|case reports]] beginning in 1999, court challenges through the 2010s, and the definitive lifting of the German ban in June 2024 — continues to shape global availability{{cite|doi=10.1055/s-0035-1558295|anchor=fb3996ee}}. The dominant kavalactone kavain directly [[glossary:potentiation|potentiates]] [[glossary:gaba-a-receptor|GABAA receptors]] at a site distinct from the [[substance_class:chemical/benzodiazepine]] [[glossary:binding-pocket]], with additional contributions from voltage-gated sodium and [[glossary:calcium-channel]] [[glossary:blockade]], [[glossary:nmda-receptor]] [[glossary:antagonism]], and reversible [[glossary:mao-b]] [[glossary:inhibition]]{{cite|doi=10.1371/journal.pone.0157700|anchor=45bbbb89}}{{cite|pubmed=12383029|anchor=e53262b4}}. dihydrokavain achieves the highest [[glossary:plasma-concentration]] (cmax ~174 ng/mL) among the six major kavalactones, with a tmax of 1–3 hours and an [[glossary:half-life]] of approximately 9 hours{{cite|doi=10.1016/j.jep.2022.115514|anchor=7c8534f8}}. The characteristic experience includes [[effect:anxiety-suppression|anxiolysis]], skeletal [[effect:muscle-relaxation]], mild [[effect:euphoria]], [[effect:sociability-enhancement]], and perioral numbness from kavain's local anesthetic activity. Effects and duration vary substantially by preparation method — traditional aqueous beverages produce a shorter, sociable experience, while standardized extracts provide sustained anxiolysis. Hepatotoxicity is the primary safety concern: approximately 100 case reports of liver injury have been documented globally, predominantly associated with organic solvent extracts, non-noble cultivars, and preparations containing aerial [[glossary:plant-material]]{{cite|doi=10.3390/ijms17040580|anchor=7412b174}}. The mechanism remains unresolved, with competing hypotheses implicating flavokavain B, pipermethystine, reactive [[glossary:metabolite|metabolites]], and mold-derived hepatotoxins. [[glossary:dependence]] risk at therapeutic doses is low, and "reverse [[glossary:tolerance]]" — decreasing dose requirements with regular use — has been described in traditional contexts{{cite|doi=10.3390/nu12103044|anchor=70d1ea84}}. One case of severe GABAergic [[glossary:withdrawal]] requiring hospitalization has been documented, though concurrent [[substance:kratom]] use confounds attribution{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=95f9ec4a}}. Herb–[[glossary:drug-interaction|drug interactions]] with benzodiazepines carry potentially life-threatening risk{{cite|pubmed=8967683|anchor=8a541550}}. No harmonized international quality standard for commercial kava products exists, and the clinical [[glossary:pharmacokinetics]] of individual kavalactones remain incompletely characterized.

'''Kava''' (''Piper methysticum'' G.Forst., Piperaceae) is a Pacific Island root beverage consumed for its [[substance_class:psychoactive/anxiolytic]] and sedative properties. Its pharmacology is driven by kavalactones — six substituted α-pyrones dominated by kavain{{cite|pubmed=12383029|anchor=b17b3232}}{{cite|doi=10.3390/nu12103044|anchor=3a253716}}. Kavain produces its principal effects by potentiating [[glossary:gaba-a-receptor|GABAA receptors]] at a site distinct from the [[substance_class:chemical/benzodiazepine]] [[glossary:binding-pocket]], yielding [[effect:anxiety-suppression|anxiolysis]] without benzodiazepine-class [[effect:cognitive-impairment]]{{cite|doi=10.1371/journal.pone.0157700|anchor=878f4226}}. Pacific Island cultures have consumed kava in ceremonial, social, and medicinal contexts for at least 3,000 years, with the plant first scientifically described by Georg Forster in 1786{{cite|doi=10.3390/nu12103044|anchor=494c1813}}{{cite|name=gbif-piper-methysticum|type=web|year=2024|title=Piper methysticum G.Forst. taxonomy and botanical identity|anchor=714dc3dc}}. Commercial kava extracts achieved top herbal medicine sales in Europe by the 1990s before regulatory bans in approximately twelve countries following [[glossary:hepatotoxicity]] [[glossary:case-report|case reports]] beginning in 1999{{cite|doi=10.1055/s-0035-1558295|anchor=a7dc7f37}}. Germany's ban was definitively lifted in June 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=3b017fb5}}, and a growing kava bar culture has emerged in the United States{{cite|doi=10.1111/dar.14080|anchor=edfff9a1}}. [[index:effects|Subjective effects]] include anxiolysis, skeletal [[effect:muscle-relaxation]], mild [[effect:euphoria]], [[effect:sociability-enhancement]], and perioral numbness. Traditional aqueous beverages produce a shorter, clear-headed sociable experience, while standardized extracts provide sustained anxiolysis — and tudei (non-noble) cultivars produce heavier [[effect:sedation]] and [[effect:nausea]] lasting up to two days{{cite|doi=10.3390/nu12103044|anchor=0bbe0f57}}. Characteristic unsought effects include gastrointestinal upset, [[effect:headache]], [[effect:dizziness]], and [[glossary:fatigue]]{{cite|doi=10.1177/0004867419891246|anchor=5340b24e}}. [[glossary:dependence]] risk at therapeutic doses is low, with "reverse [[glossary:tolerance]]" described in traditional contexts{{cite|doi=10.3390/nu12103044|anchor=4463efdb}}, though one severe GABAergic [[glossary:withdrawal]] case has been documented{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=0c01a55c}}. Hepatotoxicity is the primary safety concern — approximately 100 case reports globally, predominantly linked to organic solvent extracts and non-noble cultivars{{cite|doi=10.3390/ijms17040580|anchor=76e6c129}} — and herb–[[glossary:drug-interaction|drug interactions]] with benzodiazepines carry potentially life-threatening risk{{cite|pubmed=8967683|anchor=3bb629a4}}. Multiple [[glossary:randomized-controlled-trial|randomized controlled trials]] support anxiolytic [[glossary:efficacy]]{{cite|pubmed=12076477|anchor=c6c7e4e6}}{{cite|doi=10.1177/0004867419891246|anchor=af475bd4}}, but the hepatotoxicity mechanism remains unresolved and no harmonized international quality standard exists.

'''Kava''' (''Piper methysticum'' G.Forst., Piperaceae) is a Pacific Island root beverage prized for its calming and muscle-relaxing properties. Its dominant active constituent, kavain, is a kavalactone — a family of compounds chemically distinct from [[substance_class:psychoactive/opioid|opioids]] and [[substance_class:chemical/benzodiazepine|benzodiazepines]]{{cite|pubmed=12383029|anchor=5fd7671d}}{{cite|doi=10.3390/nu12103044|anchor=715e49a8}}. Kavain amplifies the brain's main inhibitory signal, producing relaxation without the [[effect:memory-suppression]] typical of benzodiazepines{{cite|doi=10.1371/journal.pone.0157700|anchor=7c5a46ec}}. Pacific Island cultures have used kava ceremonially, socially, and medicinally for at least 3,000 years{{cite|doi=10.3390/nu12103044|anchor=73e57695}}. Commercial extracts reached top herbal medicine sales in Europe by the 1990s before being banned in roughly twelve countries after liver injury reports emerged in 1999{{cite|doi=10.1055/s-0035-1558295|anchor=c0621310}}. Germany definitively lifted its ban in June 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=b5dff235}}, and a kava bar culture has since emerged across the United States{{cite|doi=10.1111/dar.14080|anchor=4eee3302}}. [[index:effects|Subjective effects]] include [[effect:anxiety-suppression|anxiolysis]], skeletal [[effect:muscle-relaxation]], mild [[effect:euphoria]], [[effect:sociability-enhancement]], and a distinctive perioral numbness. Traditional aqueous preparations from noble cultivars produce a clear-headed, sociable calm — lighter than [[substance:alcohol]] and without the cognitive fog of benzodiazepines. Unsought effects include [[effect:nausea]], [[effect:headache]], [[effect:dizziness]], and [[glossary:fatigue]]{{cite|doi=10.1177/0004867419891246|anchor=dab110c6}}. [[glossary:dependence]] risk at moderate doses is low; one severe [[glossary:withdrawal]] case has been documented after heavy combined kava and [[substance:kratom]] use{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=2d467fbb}}. The primary danger is liver injury — approximately 100 cases globally, most linked to organic solvent extracts and non-noble cultivars — and combining kava with benzodiazepines carries potentially life-threatening [[effect:sedation]] risk{{cite|doi=10.3390/ijms17040580|anchor=ecba245c}}{{cite|pubmed=8967683|anchor=0121a331}}. Multiple controlled trials confirm [[substance_class:psychoactive/anxiolytic]] [[glossary:efficacy]], but the liver injury mechanism remains unsolved and no international quality standard exists.

===Traditional use in the Pacific=== Kava consumption in Pacific Island cultures extends at least 3,000 years, supported by archaeological evidence and linguistic reconstruction tracing the plant's origin to Vanuatu or the broader Melanesian region{{cite|doi=10.3390/nu12103044|anchor=9e276166}}. The beverage occupies a central role in social, ceremonial, religious, and political life across Melanesia, Polynesia, and Micronesia — documented uses include community gatherings, dispute resolution, welcoming of guests, communication with ancestors, and medicinal applications for [[effect:anxiety]], [[effect:insomnia]], and pain{{cite|pubmed=12383029|anchor=9a2c041c}}. Traditional preparation involved chewing fresh root, mixing the masticated material with water, and straining through plant fiber{{cite|doi=10.3390/nu12103044|anchor=ad6cddd7}}. Later methods substituted stone pounding or mechanical grinding. The resulting opaque, tan-brown liquid is consumed from coconut shells. ===Western discovery and commercialization=== Georg Forster formally described and named ''Piper methysticum'' in 1786 in ''De Plantis Esculentis Insularum Oceani Australis'', based on specimens from Captain Cook's second Pacific voyage (1772–1775){{cite|name=gbif-piper-methysticum|type=web|year=2024|title=Piper methysticum G.Forst. taxonomy and botanical identity|anchor=929dc6fb}}. The specific epithet ''methysticum'' derives from Latin for "intoxicating." Modern phytochemical characterization of kavalactones proceeded through the 1960s–1980s{{cite|pubmed=12383029|anchor=0f2cc715}}. By the 1990s, commercial kava extracts — notably the acetonic extract WS1490 — had reached top-10 herbal medicine sales in Germany and across Europe and North America{{cite|pubmed=16005588|anchor=83c204a3}}. The Cochrane Collaboration published reviews affirming [[substance_class:psychoactive/anxiolytic]] [[glossary:efficacy]] in 2000 and 2002{{cite|pubmed=10653213|anchor=897ff2bd}}{{cite|pubmed=12076477|anchor=653497f0}}. ===Regulatory crisis and modern era=== [[glossary:case-report|Case reports]] of severe [[glossary:hepatotoxicity]] appeared beginning in 1999–2001{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=adca1e97}}{{cite|pubmed=12733846|anchor=b4bf89c8}}, prompting regulatory bans in approximately twelve countries including Germany, France, the United Kingdom, Canada, and Australia{{cite|pubmed=14737001|anchor=9041d23b}}. Vanuatu enacted the Kava Act in 2002, defining noble cultivar standards and restricting exports to approved varieties{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=896abee9}}. German administrative courts began overturning the national ban circa 2013–2015, ruling the restriction "inappropriate and even associated with an increased risk due to higher risk inherent to therapeutic alternatives"{{cite|doi=10.1055/s-0035-1558295|anchor=96594da5}}. The Cologne Administrative Court definitively lifted the ban on June 18, 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=19ccaff9}}. A landmark 16-week [[glossary:randomized-controlled-trial]] for generalized anxiety [[glossary:disorder]] was published in 2020{{cite|doi=10.1177/0004867419891246|anchor=1aa39f2f}}, and a growing kava bar culture has emerged in the United States — particularly in Florida and Pacific coast states{{cite|doi=10.1111/dar.14080|anchor=f29292b8}}.

===Traditional use in the Pacific=== Kava consumption in Pacific Island cultures extends at least 3,000 years, with archaeological and linguistic evidence pointing to Vanuatu and the Melanesian region as the plant's origin{{cite|doi=10.3390/nu12103044|anchor=e8c8982e}}. Documented uses span community gatherings, dispute resolution, welcoming of guests, communication with ancestors, and treatment of [[effect:anxiety]], [[effect:insomnia]], and pain{{cite|pubmed=12383029|anchor=1a9b1053}}. ===Western discovery and commercialization=== Georg Forster formally described and named ''Piper methysticum'' in 1786, based on specimens from Captain Cook's second Pacific voyage{{cite|name=gbif-piper-methysticum|type=web|year=2024|title=Piper methysticum G.Forst. taxonomy and botanical identity|anchor=9a6c30d0}}. By the 1990s, commercial kava extracts had reached top-10 herbal medicine sales across Germany, Europe, and North America{{cite|pubmed=16005588|anchor=f396acb8}}, and the Cochrane Collaboration published reviews affirming [[substance_class:psychoactive/anxiolytic]] [[glossary:efficacy]]{{cite|pubmed=10653213|anchor=c0c5f9df}}{{cite|pubmed=12076477|anchor=277187f9}}. ===Regulatory crisis and modern era=== Liver injury [[glossary:case-report|case reports]] beginning in 1999–2001 prompted bans in approximately twelve countries, including Germany, France, the United Kingdom, and Canada{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=04ed2a91}}{{cite|pubmed=12733846|anchor=4f780b64}}{{cite|pubmed=14737001|anchor=79bec077}}. German courts began overturning the ban around 2013–2015{{cite|doi=10.1055/s-0035-1558295|anchor=a9f35fd5}}, with the Cologne Administrative Court definitively lifting it on June 18, 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=5b2ff7c1}}. A 16-week controlled trial for generalized anxiety [[glossary:disorder]] followed in 2020{{cite|doi=10.1177/0004867419891246|anchor=8d4e733a}}, and kava bars are now established across Florida and Pacific coast states{{cite|doi=10.1111/dar.14080|anchor=4b16682b}}.

===Discovery and early scientific record=== Georg Forster described and named ''Piper methysticum'' in 1786 in ''De Plantis Esculentis Insularum Oceani Australis Commentatio Botanica'', based on plant specimens collected during Captain James Cook's second voyage (1772–1775) to the South Pacific{{cite|name=gbif-piper-methysticum|type=web|year=2024|title=Piper methysticum G.Forst. taxonomy and botanical identity|anchor=62e9ff13}}. The specific epithet ''methysticum'' derives from Latin for "intoxicating." During the late 19th century, kava entered European pharmacopoeias as a treatment for urinary tract infections and nervous conditions, though the true chemistry of its active constituents was not resolved until the 20th century{{cite|doi=10.3390/nu12103044|anchor=46da3fb8}}. ===Traditional use in the Pacific=== Kava consumption in Pacific Island cultures extends at least 3,000 years, supported by archaeological evidence and linguistic reconstruction tracing the plant's origin to Vanuatu or the broader Melanesian region{{cite|doi=10.3390/nu12103044|anchor=0223201e}}. The beverage occupies a central position in social, ceremonial, religious, and political life across Melanesia, Polynesia, and Micronesia. Documented traditional uses include community gatherings, dispute resolution, welcoming of guests, communication with ancestors and deities, and medicinal applications for [[effect:anxiety]], [[effect:insomnia]], pain, and urinary complaints{{cite|pubmed=12383029|anchor=0e306a1b}}. Traditional preparation involved chewing fresh kava root — a practice noted by early European explorers — followed by mixing the masticated material with water and straining through plant fiber. Later methods substituted stone pounding or mechanical grinding{{cite|doi=10.3390/nu12103044|anchor=2c0763f0}}. The resulting opaque, tan-brown liquid is consumed from coconut shells. The chewing method, now less common, may alter kavalactone content through salivary amylase activity. ===Western research and commercial development=== Modern phytochemical characterization of kavalactones began in the 1960s–1980s, establishing the structural and pharmacological basis for kava's effects{{cite|pubmed=12383029|anchor=f5c2a9a1}}. By the 1990s, commercial kava extracts — notably the acetonic extract WS1490 — achieved top-10 herbal medicine sales status in Germany and across Europe and North America{{cite|pubmed=16005588|anchor=d5bab079}}. The Cochrane Collaboration published reviews affirming [[substance_class:psychoactive/anxiolytic]] [[glossary:efficacy]] in 2000 and 2002{{cite|pubmed=10653213|anchor=f89bbe41}}{{cite|pubmed=12076477|anchor=8dc83082}}. ===Regulatory crisis and resolution=== [[glossary:case-report|Case reports]] of severe [[glossary:hepatotoxicity]] appeared beginning in 1999–2001{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=6336d262}}{{cite|pubmed=12733846|anchor=1d6932dd}}, prompting regulatory bans in approximately twelve countries including Germany (2002), France, the United Kingdom, Canada, Switzerland, and Australia{{cite|pubmed=14737001|anchor=8cc7bce9}}. Vanuatu enacted the Kava Act in 2002, defining noble cultivar standards and restricting export to approved varieties{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=46c02412}}. Scientific debate over hepatotoxicity causality continued through the following decade, with critical analyses questioning the strength of causality assessment in most reported cases{{cite|doi=10.1097/MEG.0b013e3283036768|anchor=5bcbe429}}. German administrative courts began overturning the national ban circa 2013–2015, finding the restriction "inappropriate and even associated with an increased risk due to higher risk inherent to therapeutic alternatives"{{cite|doi=10.1055/s-0035-1558295|anchor=58765e6b}}. The Administrative Court of Cologne definitively lifted the ban on June 18, 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=84733dec}}. The landmark 16-week [[glossary:randomized-controlled-trial]] for generalized anxiety [[glossary:disorder]] was published in 2020{{cite|doi=10.1177/0004867419891246|anchor=2c4a4229}}, and a growing kava bar culture has emerged in the United States — particularly in Florida, California, and Pacific coast states{{cite|doi=10.1111/dar.14080|anchor=376c4c86}}.

''Piper methysticum'' G.Forst. belongs to the pepper family (Piperaceae), which also includes black pepper (''Piper nigrum''). Kava is exclusively a cultivated plant — it cannot reproduce sexually and is propagated entirely through stem cuttings{{cite|doi=10.3390/nu12103044|anchor=c1182122}}. The distinction between '''noble''' and '''non-noble (tudei)''' cultivars matters significantly for both effect character and safety. The plant's native range spans the western Pacific, with Vanuatu and the Melanesian archipelago identified as the centre of origin{{cite|doi=10.3390/nu12103044|anchor=f7f84a72}}. It grows in humid tropical lowland conditions — fertile volcanic soils below about 300 metres [[glossary:elevation]]. Commercial cultivation extends across Vanuatu, Fiji, Tonga, Samoa, and Hawai'i. Kava grows as a robust shrub reaching 2–3 metres, with large heart-shaped leaves and prominent nodes on smooth green stems. The root system — a dense mass of lateral roots and a central rhizome — is the harvested part. Noble and tudei cultivars are visually indistinguishable{{cite|doi=10.1055/s-0030-1250290|anchor=205c91c9}}{{cite|doi=10.1002/ptr.3464|anchor=e01ee7b0}}, which creates an identification problem for buyers and regulators alike.

''Piper methysticum'' is not a true wild species but represents a complex of sterile cultivars derived from the wild ancestor ''Piper wichmanii'' C.DC., native to Papua New Guinea, the Solomon Islands, and Vanuatu{{cite|doi=10.3390/nu12103044|anchor=748ae3ac}}{{cite|name=gbif-piper-methysticum|type=web|year=2024|title=Piper methysticum G.Forst. taxonomy and botanical identity|anchor=8945d582}}. Because ''P. methysticum'' was formally named first (1786), it retains taxonomic priority over ''P. wichmanii'' (1910); some authorities treat the two as conspecific varieties. All cultivated kava plants are universally sterile — producing no viable seeds — and are propagated exclusively by stem cuttings{{cite|doi=10.3390/nu12103044|anchor=90ff9dbe}}. Vanuatu is considered the primary center of origin and genetic diversity. Austronesian peoples spread cultivated kava across the Pacific over millennia; it is now grown commercially in Vanuatu, Fiji, Tonga, Samoa, Hawaii, and the Federated States of Micronesia. The plant requires warm, humid tropical conditions, well-drained volcanic soils, and partial shade. ===Morphology=== Kava is an erect perennial shrub, 1.5–3 m tall, bearing large cordate (heart-shaped) alternate leaves measuring 10–20 cm across with prominent venation, jointed stems with visible leaf nodes, and inconspicuous flower spikes. The medicinally active portions are the underground rhizomes and lateral roots{{cite|doi=10.3390/nu12103044|anchor=363bea67}}. No significant [[glossary:misidentification]] risk exists with toxic look-alike species within its native range. ===Noble and non-noble cultivars=== A critical pharmacological and safety distinction exists between '''noble''' and '''non-noble''' (tudei) cultivars{{cite|doi=10.1055/s-0030-1250290|anchor=e7a9a145}}{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=1802eda1}}{{cite|doi=10.3390/nu12103044|anchor=19790f9f}}: * '''Noble kava''' includes at least 28 named cultivars approved for export under Vanuatu's Kava Act 2002 (e.g., Borogu, Palarasul, Melo Melo). Noble cultivars are kavain-dominant, well-tolerated with regular use, and recommended for medicinal applications. Borogu is specifically recommended in safety consensus literature as the preferred cultivar for medicinal preparations{{cite|doi=10.1002/ptr.3464|anchor=15dc1160}}{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=97e069c3}}. * '''Tudei (two-day) kava''' and other non-noble cultivars contain higher proportions of dihydrokavain and dihydromethysticin relative to kavain, produce effects persisting up to two days with significant [[effect:nausea]] and hangover-like [[glossary:sequela|sequelae]], and are implicated in [[glossary:hepatotoxicity]] concerns. Export of tudei kava is prohibited under Vanuatu law. * '''Wild kava''' (''P. wichmanii'') is the progenitor species and is not used for [[glossary:human-consumption]]. Noble and non-noble cultivars cannot be reliably distinguished by morphological examination alone; chemotype verification by HPLC or trained chemosensory evaluation is required for definitive identification{{cite|doi=10.1055/s-0030-1250290|anchor=16565e91}}{{cite|doi=10.1002/ptr.3464|anchor=79d84128}}.

''Piper methysticum'' G.Forst. belongs to the pepper family (Piperaceae), a large tropical family that includes black pepper (''Piper nigrum''). The species is a dioecious perennial shrub; its specific epithet, "intoxicating," reflects the sedative properties of its root system. Kava is exclusively a cultivated plant — it is sterile and does not reproduce sexually in the wild, propagated solely through stem cuttings{{cite|doi=10.3390/nu12103044|anchor=366872ce}}. The plant's native range spans the western Pacific, with Vanuatu and the broader Melanesian archipelago identified as the centre of origin{{cite|doi=10.3390/nu12103044|anchor=a81b049b}}. It grows in humid tropical lowland conditions, thriving in well-drained, fertile volcanic soils at [[glossary:elevation|elevations]] below approximately 300 metres. Today kava is cultivated commercially across Vanuatu, Fiji, Tonga, Samoa, and Hawai'i. Kava grows as a robust, erect shrub reaching 2–3 metres in height, with large, heart-shaped (cordate) leaves on smooth green stems with prominent nodes. The root system — a dense mass of lateral roots and central rhizome — is the harvested portion. Mature plants are typically harvested at 3–5 years of age; the Vanuatu Kava Act specifies a minimum 5-year harvest age for export-grade material{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=95c9adcc}}. The distinction between '''noble''' and '''non-noble (tudei)''' cultivars is critical for both safety and effect quality. Noble cultivars — the only varieties approved for export under Vanuatu law — produce a clear-headed, sociable experience. Tudei cultivars, visually indistinguishable from noble varieties{{cite|doi=10.1055/s-0030-1250290|anchor=f9782772}}{{cite|doi=10.1002/ptr.3464|anchor=5d61b131}}, contain elevated levels of dihydromethysticin and flavokavain B and produce heavy [[effect:sedation]], [[effect:nausea]], and residual lethargy lasting up to two days{{cite|doi=10.3390/nu12103044|anchor=b6eb7c25}}.

Six kavalactones (kavapyrones) — a class of substituted α-pyrones unique to ''Piper methysticum'' — account for approximately 96% of the total lipid resin in kava root and constitute the primary pharmacologically active compounds{{cite|pubmed=12383029|anchor=d9605558}}{{cite|doi=10.3390/nu12103044|anchor=75269067}}. ===Major kavalactones===

Kavalactone	Formula	MW (g/mol)	Key pharmacological notes
Kavain (K)	C14H14O3	230.26	Dominant in noble cultivars (~44% of extract); primary anxiolytic; direct GABAA potentiator
Dihydrokavain (DHK)	C14H16O3	232.27	Saturated kavain analog; achieves highest plasma Cmax despite lower extract proportion
methysticin (M)	C15H14O5	274.27	Contains methylenedioxy group; potent CYP2C19 inhibitor in vitro
dihydromethysticin (DHM)	C15H16O5	276.28	Saturated methysticin; significant CYP2C9/2C19 inhibition; heavy sedation contributor
yangonin (Y)	C15H14O4	258.27	Fully conjugated α-pyrone; CB1 agonist activity reported{{flag|citation-needed}}
desmethoxyyangonin (DMY)	C14H12O3	228.24	Smallest major kavalactone; CYP2C9/2C19 inhibitor at Ki 5–10 µM{{cite|pubmed=16033948|anchor=458af0c9}}

Pacific Island kava producers classify cultivars using a six-digit '''chemotype code''' listing the six kavalactones in order of decreasing concentration — for example, 421356 for a kavain-dominant noble variety{{cite|doi=10.3390/nu12103044|anchor=01ba4896}}. Noble cultivars typically begin with 4 (kavain-dominant) or 2 (dihydrokavain-dominant). Kavain-dominant chemotypes are associated with more pleasant [[substance_class:psychoactive/anxiolytic]] effects, while DHK/DHM-dominant chemotypes produce heavier [[effect:sedation]] with more [[glossary:adverse-effects]]. ===Concentration and preparation variability=== Dried noble kava root contains 3–20% kavalactones by dry weight{{cite|doi=10.3390/nu12103044|anchor=3bbdb8f7}}{{cite|name=kava-dosage-industry|type=web|year=2024|title=Kava traditional preparation kavalactone content per shell|anchor=68a3df26}}. Standardized pharmaceutical extracts (e.g., WS1490) are formulated to contain 70–240 mg kavalactones per dose{{cite|pubmed=15934028|anchor=47d514b7}}. Commercial dietary supplement labeling accuracy is variable, with significant discrepancies between stated and actual kavalactone content reported{{cite|doi=10.3390/nu12103044|anchor=14dc7617}}. Extraction solvent significantly alters constituent ratios. '''Aqueous (traditional) extraction''' preferentially extracts more polar kavalactones (kavain and dihydrokavain are relatively more water-soluble) and yields lower total kavalactone content but may extract less flavokavain B{{cite|doi=10.1016/j.jep.2009.03.038|anchor=b8ccff3b}}{{cite|doi=10.1021/tx100412m|anchor=6c4115d8}}. '''Acetonic and ethanolic extraction''' achieves higher total kavalactone yield and additionally extracts lipophilic minor constituents including flavokavains A, B, and C — chalcones of toxicological significance{{cite|doi=10.1016/j.jep.2009.03.038|anchor=4145862e}}. ===Minor constituents of toxicological significance=== '''Flavokavain B''' is a [[glossary:naturally-occurring|naturally occurring]] chalcone identified as the most [[glossary:hepatotoxicity|hepatotoxic]] constituent in HepG2 cell viability [[glossary:assay|assays]], inducing GSH-sensitive [[glossary:oxidative-stress]] via IKK/NF-κB and MAPK pathways{{cite|pubmed=16608246|anchor=94f71185}}. Content is higher in non-noble cultivars and organic solvent extracts. Flavokavain A demonstrates potent anticancer properties (apoptosis induction in prostate and bladder cancer cells) alongside CYP [[glossary:inhibition]] [[glossary:in-vitro|in vitro]]{{cite|doi=10.1016/j.jep.2016.06.039|anchor=16b2bbbe}}. '''Pipermethystine''', an alkaloid concentrated in leaves and stem peelings rather than roots and rhizomes, produces 90% HepG2 [[glossary:cell-death]] at 100 µM versus negligible kavalactone [[glossary:cytotoxicity]] at the same concentration{{cite|pubmed=14737001|anchor=b9c055e1}}. It disrupts mitochondrial function, decreases ATP, and induces caspase-3-mediated apoptosis. The presence of pipermethystine in commercial supplements containing aerial [[glossary:plant-material]] has been implicated in hepatotoxicity cases{{cite|doi=10.1021/tx100412m|anchor=cf618832}}{{cite|pubmed=14737001|anchor=37ca0d08}}.

Kava's psychoactive properties come from '''kavalactones''' — a family of compounds making up approximately 96% of the lipid resin in dried root material{{cite|pubmed=12383029|anchor=8b4eda0e}}{{cite|doi=10.3390/nu12103044|anchor=6777e026}}. Six major kavalactones dominate: kavain, dihydrokavain, methysticin, dihydromethysticin, desmethoxyyangonin, and yangonin. Kavain is typically the most abundant — around 44% of extract content — and is the primary driver of [[substance_class:pharmacological/gaba-system]] activity{{cite|doi=10.1371/journal.pone.0157700|anchor=fbd07f6d}}. The kavalactones work together rather than in isolation. Kavain and dihydromethysticin show [[glossary:additive-effects]] on brain signaling{{cite|pubmed=9194150|anchor=5b0f1e5f}}, and taking whole extract triples kavain's blood levels compared to kavain alone, through [[glossary:inhibition]] of the [[glossary:enzyme|enzymes]] that break it down{{cite|pubmed=16033948|anchor=74363b86}}. Two safety-relevant compounds also warrant attention: '''flavokavain B''' — elevated in non-noble cultivars and organic solvent extracts — damages liver cells via [[glossary:oxidative-stress]]{{cite|pubmed=16608246|anchor=1b0f4033}}; and '''pipermethystine''', concentrated in leaves and stems rather than the root, caused 90% hepatocyte death at high concentrations in cell studies{{cite|pubmed=14737001|anchor=dc42afcc}}. Kavalactone concentrations vary significantly across cultivars, plant parts, harvest age, and preparation method{{cite|doi=10.3390/nu12103044|anchor=5f05574e}}. Noble cultivars generally show higher kavain-to-dihydromethysticin ratios than tudei varieties. Commercial products frequently show significant discrepancy between labeled and actual kavalactone content{{cite|doi=10.3390/nu12103044|anchor=1da28d4e}}, and no international standard governs kavalactone quantification.

Kava's psychoactive properties derive from '''kavalactones''' — a family of substituted α-pyrones that account for approximately 96% of the lipid resin in dried root material{{cite|pubmed=12383029|anchor=e5f8c2d4}}{{cite|doi=10.3390/nu12103044|anchor=93cc2391}}. Six major kavalactones dominate: kavain, dihydrokavain, methysticin, dihydromethysticin, desmethoxyyangonin, and yangonin. Kavain is typically the most abundant, comprising roughly 44% of extract content, and serves as the primary driver of [[glossary:gaba-a-receptor]] [[glossary:potentiation]]{{cite|doi=10.1371/journal.pone.0157700|anchor=592724b3}}. The kavalactones function as a pharmacological ensemble rather than through any single constituent. Kavain and dihydromethysticin show [[glossary:additive-effects]] on [[glossary:glutamate]]-mediated field potentials in [[glossary:hippocampus|hippocampal]] tissue{{cite|pubmed=9194150|anchor=c3aee43e}}, and whole-extract co-administration triples kavain's [[glossary:plasma-concentration|plasma exposure]] in [[glossary:animal-model|animal models]] through self-[[glossary:inhibition]] of CYP [[glossary:metabolism]]{{cite|pubmed=16033948|anchor=f3a22c42}} — suggesting that the extract matrix meaningfully alters individual kavalactone [[glossary:pharmacokinetics]]. Whether this entourage effect extends to clinical [[substance_class:psychoactive/anxiolytic]] outcomes in humans remains uncharacterized in controlled studies. '''Flavokavain B''', a chalcone rather than a true kavalactone, warrants specific mention as a safety-relevant constituent. It is present at higher concentrations in non-noble (tudei) cultivars and in organic solvent extracts, and has demonstrated [[glossary:cytotoxicity]] in liver cell models via [[glossary:oxidative-stress]] pathways{{cite|pubmed=16608246|anchor=bee2008f}}. '''Pipermethystine''', an alkaloid concentrated in aerial [[glossary:plant-material]] (leaves, stems, peelings), produced 90% hepatocyte death at high concentrations [[glossary:in-vitro|in vitro]] via mitochondrial apoptosis{{cite|pubmed=14737001|anchor=17fca8ed}}. Both compounds are implicated in competing [[glossary:hepatotoxicity]] hypotheses. Kavalactone concentrations vary significantly across cultivars, plant parts, harvest age, and preparation method{{cite|doi=10.3390/nu12103044|anchor=7b2a3d9d}}. Noble cultivars generally show higher kavain-to-dihydromethysticin ratios than tudei varieties. Commercial products show significant discrepancy between labeled and actual kavalactone content{{cite|doi=10.3390/nu12103044|anchor=c1f22d43}}, and no internationally harmonized analytical standard governs kavalactone quantification in consumer products.

===Receptor targets and mechanism=== Kava's calming effects arise from activity across several brain systems at once. Kavain amplifies [[glossary:gaba]] — the brain's main inhibitory signal — at a site distinct from [[substance_class:chemical/benzodiazepine|benzodiazepines]], overlapping instead with where general anesthetics act{{cite|doi=10.1371/journal.pone.0157700|anchor=517aace2}}. It also blocks the electrical [[glossary:channel|channels]] that allow nerve cells to fire{{cite|pubmed=9194150|anchor=129f6049}} and mildly inhibits an [[glossary:enzyme]] that breaks down [[glossary:dopamine]], contributing to elevated mood{{cite|doi=10.3109/00048674.2010.522554|anchor=c967056d}}. ===Neuroimaging and downstream effects=== An 8-week controlled trial using brain imaging found decreased GABA levels in a frontal brain region after regular kava use at 120 mg kavalactones twice daily{{cite|doi=10.3390/nu15214586|anchor=e9d8c266}}, alongside decreased [[glossary:expression]] of GABA [[glossary:receptor]] genes{{cite|doi=10.1002/ptr.7999|anchor=2cd0146d}}. Several kavalactones also inhibit the [[glossary:reuptake]] of [[glossary:norepinephrine]] and dopamine{{cite|doi=10.3109/00048674.2010.522554|anchor=535646fe}}. {{DiscoverMore|Open Questions}} Three puzzles remain unsolved. First, "reverse [[glossary:tolerance]]" — regular users needing less kava over time — has no established pharmacological explanation and runs counter to typical receptor-mediated tolerance{{cite|doi=10.3390/nu12103044|anchor=9a17b50d}}. Second, no formal human [[glossary:bioavailability]] study has been published for any individual kavalactone. Third, the relative contribution of each kavalactone versus their combined action to overall [[substance_class:psychoactive/anxiolytic]] effect remains uncharacterized in controlled human studies. {{/DiscoverMore}}

===Receptor targets and mechanism=== Kava's [[substance_class:psychoactive/anxiolytic]] profile results from polypharmacological activity across multiple [[glossary:receptor-system|receptor systems]]. Kavain directly [[glossary:potentiation|potentiates]] [[glossary:gaba-a-receptor|GABAA receptors]], with greater effect at extrasynaptic α4β2δ [[glossary:receptor|receptors]] than at synaptic subtypes{{cite|doi=10.1371/journal.pone.0157700|anchor=082976e1}}. This action is not blocked by flumazenil, confirming a [[glossary:binding-site]] distinct from [[substance_class:chemical/benzodiazepine|benzodiazepines]] — instead overlapping with the general anesthetic site{{cite|doi=10.1371/journal.pone.0157700|anchor=8f8451df}}. Additional targets include voltage-gated sodium and [[glossary:calcium-channel]] [[glossary:blockade]], [[glossary:nmda-receptor]] [[glossary:antagonism]] in [[glossary:hippocampus|hippocampal]] [[glossary:circuit|circuits]]{{cite|pubmed=9194150|anchor=c6107420}}, and reversible [[glossary:mao-b]] [[glossary:inhibition]] contributing to elevated [[glossary:dopamine]] levels{{cite|doi=10.3109/00048674.2010.522554|anchor=f95bb097}}. ===Neuroimaging and downstream effects=== An 8-week [[glossary:randomized-controlled-trial]] using proton magnetic resonance spectroscopy found decreased [[glossary:gaba]] levels in the dorsal anterior cingulate [[glossary:cortex]] following kava treatment at 120 mg kavalactones twice daily{{cite|doi=10.3390/nu15214586|anchor=b4744e96}}. Peripheral gene [[glossary:expression]] analysis from the same [[glossary:cohort]] showed decreased GABAA rho [[glossary:subunit]] expression{{cite|doi=10.1002/ptr.7999|anchor=3138c593}}. [[glossary:norepinephrine|Noradrenaline]] and [[substance_class:pharmacological/dopamine-reuptake-inhibitor]] has also been documented for several kavalactones{{cite|doi=10.3109/00048674.2010.522554|anchor=7418ca77}}. {{DiscoverMore|Open Questions}} Three puzzles remain unresolved. First, "reverse [[glossary:tolerance]]" — regular users requiring less kava over time — has no established pharmacological mechanism and runs counter to typical receptor-mediated tolerance{{cite|doi=10.3390/nu12103044|anchor=c2783864}}. Second, no formal human oral [[glossary:bioavailability]] study has been published for any individual kavalactone. Third, the relative contributions of individual kavalactones versus their combined action to the overall anxiolytic effect remain uncharacterized in controlled human studies. {{/DiscoverMore}}

Kava's experiential character is shaped more by preparation and cultivar than by dose alone. Traditional aqueous beverages from noble cultivars produce a clear-headed, sociable calm with prominent [[effect:muscle-relaxation]] and a characteristic numbness of the lips and mouth. Standardized pharmaceutical extracts lean toward sustained [[effect:anxiety-suppression|anxiolysis]] with less of the acute social quality. Tudei cultivars produce a qualitatively heavier experience — [[effect:sedation]], [[effect:nausea]], and [[glossary:fatigue]] that can persist for two days. Kava sits between [[substance_class:chemical/benzodiazepine|benzodiazepines]] and [[substance:alcohol]] as a calming agent, but diverges meaningfully from both. Unlike benzodiazepines, kava does not impair memory or driving performance at therapeutic doses{{cite|doi=10.1080/15389588.2012.682233|anchor=3cfbba97}}. Unlike alcohol, it produces anxiolysis and muscle relaxation without behavioral [[effect:disinhibition]] or next-morning hangover — though non-noble cultivars partially erode that advantage.

This section describes the major kava preparation forms, their [[glossary:dose-range|dose ranges]], and preparation-specific onset and duration characteristics. The Dose by preparation card provides a structured summary; the text below contextualizes each preparation. ===Traditional aqueous beverage=== Dried or fresh noble kava root and rhizome are ground or pounded, mixed with cold to lukewarm water (hot water degrades kavalactones), kneaded through fibrous cloth or plant fiber, and strained. The resulting opaque, tan-brown liquid is served in coconut shells — termed ''bilo'' in Fiji and ''ipu'' in Hawaii{{cite|doi=10.3390/nu12103044|anchor=1de563cf}}. '''Traditional beverage (oral):''' Estimated 150–500 mg kavalactones per shell (120–180 mL), depending on cultivar, root-to-water ratio, and preparation technique{{cite|name=kava-dosage-industry|type=web|year=2024|title=Kava traditional preparation kavalactone content per shell|anchor=e36d4785}}. Community sessions typically involve 2–4 shells. Onset 15–30 min; peak 1–2 h; total duration 2–4 h. {{flag|safety-citation-needed}} Kavalactone content per traditional serving has not been quantified by peer-reviewed HPLC analysis; the 150–500 mg range is derived from non-peer-reviewed industry sources. Subjective character at common doses includes mild to moderate [[effect:sedation]], [[effect:muscle-relaxation]], [[effect:sociability-enhancement]], mild [[effect:euphoria]], reduced [[effect:anxiety]], and perioral numbness — a local anesthetic effect of kavain. [[effect:cognitive-impairment]] is not prominent at moderate doses{{cite|pubmed=12383029|anchor=5bd2e63a}}{{cite|doi=10.3109/00048674.2010.522554|anchor=6b4b93a3}}. ===Standardized pharmaceutical extract=== Standardized kava extracts include WS1490 (acetonic extract, ~70% kavalactones) and aqueous noble cultivar formulations developed for clinical research (e.g., the KALM trial formulation). Clinical dosing is expressed as kavalactone content per dose. '''Standardized extract (oral capsule/tablet):''' Clinical therapeutic dose 120 mg kavalactones twice daily (240 mg/day), as used in the 16-week KALM generalized anxiety [[glossary:disorder]] trial{{cite|doi=10.1177/0004867419891246|anchor=918c1e78}}. Maximum recommended medicinal dose of 250 mg kavalactones/day has been proposed{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=f5d7f8cf}}. Meta-analytic effective range: 70–210 mg kavalactones per dose{{cite|pubmed=12076477|anchor=c815092f}}{{cite|pubmed=10653213|anchor=57db1aa1}}. Acute study dose: 180 mg kavalactones single dose{{cite|doi=10.1080/15389588.2012.682233|anchor=9640b852}}{{cite|doi=10.1002/hup.2216|anchor=fe7988a8}}. Onset 30–60 min; peak 1.5–2.5 h (consistent with tmax 1–3 h); total duration 4–8 h. A single 180 mg kavalactone dose does not impair simulated driving performance; in contrast, oxazepam 30 mg significantly slows braking reaction time and reduces alertness{{cite|doi=10.1080/15389588.2012.682233|anchor=ee4f45e3}}. ===Instant (micronized) kava powder=== A modern preparation in which kava root is finely milled and mixed directly into water without straining. This format contains more plant particulates, potentially including higher flavokavain content. No peer-reviewed dose-response or pharmacokinetic data specific to instant kava preparations were identified{{flag|citation-needed}}. Kavalactone content per weight is assumed equivalent to traditional preparation material. Anecdotal reports suggest greater gastrointestinal discomfort compared to strained preparations. ===Dose modifiers=== Cultivar chemotype significantly affects the experience: kavain-dominant noble cultivars produce a more pleasant [[substance_class:psychoactive/anxiolytic]] effect, while DHK/DHM-dominant cultivars produce heavier sedation with more [[glossary:adverse-effects]]{{cite|doi=10.3390/nu12103044|anchor=0ddfee47}}. Regular Pacific kava users report "reverse [[glossary:tolerance]]" — requiring less kava over time to achieve desired effects — through a mechanism that remains poorly understood. Fatty meals may increase kavalactone [[glossary:bioavailability]] via enhanced lipophilic [[glossary:absorption]]. [[glossary:potency]] varies substantially across cultivars and harvest batches; commercial products show significant variation between labeled and actual kavalactone content{{cite|doi=10.3390/nu12103044|anchor=149663e6}}. No peer-reviewed dose data exist for kava tinctures or concentrated liquid extracts, which represent an increasingly common commercial format. No systematic study of doses consumed in modern kava bar settings has been published.

Kava's experiential character is shaped more by preparation and cultivar than by dose alone. Traditional aqueous beverages from noble cultivars produce a distinctively clear-headed [[glossary:sociability]] with prominent [[effect:muscle-relaxation]] and perioral numbness — relaxing without sedating at moderate intake. Standardized pharmaceutical extracts emphasize sustained [[effect:anxiety-suppression|anxiolysis]] with less of the acute social dimension, while tudei cultivars produce a qualitatively heavier experience dominated by [[effect:sedation]] and [[effect:nausea]]. [[glossary:set-and-setting]] interact substantially with these preparation differences: the communal context of traditional ceremony amplifies the prosocial qualities. Pharmacologically, kava sits between [[substance_class:chemical/benzodiazepine|benzodiazepines]] and [[substance:alcohol]] as a GABAergic [[substance_class:psychoactive/anxiolytic]], but diverges from both. It does not produce the [[effect:cognitive-impairment]] or amnestic effects of benzodiazepines at therapeutic doses, and does not impair driving performance at clinical doses where oxazepam does{{cite|doi=10.1080/15389588.2012.682233|anchor=3c2dee0b}}. Compared to alcohol, kava produces anxiolysis and muscle relaxation without [[effect:disinhibition]]-driven behavioral escalation or next-day hangover — though non-noble cultivars partially erode this advantage.

Kava is available in several distinct forms, each with different onset, duration, and effect character. * '''Traditional aqueous beverage:''' Fresh or dried root is ground, kneaded in water, and strained through cloth{{cite|doi=10.3390/nu12103044|anchor=546445e8}}. A typical serving contains approximately 150–250 mg of kavalactones. Onset: 20–30 minutes. Duration: 2–4 hours. Produces the classic clear-headed [[glossary:sociability]] and perioral numbness. Aqueous extraction is less efficient than organic solvents — thought to reduce, though not eliminate, [[glossary:hepatotoxicity]] risk{{cite|doi=10.1111/j.1708-8305.2008.00259.x|anchor=661cd995}}. * '''Standardized extracts (capsules and tablets):''' Commercial supplements typically contain acetonic or ethanolic extracts standardized to 30–70% kavalactones. Clinical trials have most commonly used 120–240 mg kavalactones per day{{cite|doi=10.1177/0004867419891246|anchor=897e7d92}}. Onset: 30–60 minutes. Duration: 4–8 hours. Emphasizes sustained [[effect:anxiety-suppression|anxiolysis]] over the acute sociable character of aqueous preparations. Organic solvent extracts carry the strongest association with hepatotoxicity [[glossary:case-report|case reports]]{{cite|doi=10.3390/ijms17040580|anchor=a3bf5212}}. * '''Kava bar beverages:''' US kava bars{{cite|doi=10.1111/dar.14080|anchor=fb460ed5}} typically serve aqueous preparations from noble cultivar root powder, shaken and strained to order. Kavalactone content per serving varies significantly by recipe and root source. Effect profile resembles traditional aqueous preparations — sociable, relaxing, and relatively short-acting. Some bars also serve concentrated shots with higher kavalactone loads per volume. * '''Instant and micronized kava:''' Dehydrated aqueous extract or finely milled root powder stirred directly into water without straining. Kavalactone content per gram is generally higher than traditional grind due to reduced fiber. Onset and duration approximate traditional aqueous preparations. [[glossary:potency]] varies significantly between products and batches{{cite|doi=10.3390/nu12103044|anchor=53c1a123}}. Onset and [[glossary:intensity]] differ substantially between preparations — standardized extracts act more slowly and last considerably longer than traditional aqueous beverages.

====Traditional aqueous beverage==== The oldest and most widely consumed form. Fresh or dried root is ground, kneaded in water, and strained through cloth or plant fiber{{cite|doi=10.3390/nu12103044|anchor=99019b40}}. Kavalactone content varies with root quality, water ratio, and kneading duration, but a typical serving shell contains approximately 150–250 mg of kavalactones. Onset occurs within 20–30 minutes; duration is 2–4 hours. The experience is characterized by clear-headed [[glossary:sociability]], [[effect:muscle-relaxation]], and perioral numbness. The aqueous method extracts kavalactones less efficiently than organic solvents, which proponents cite as a protective factor against [[glossary:hepatotoxicity]] — though aqueous preparations are not free of hepatotoxic risk{{cite|doi=10.1111/j.1708-8305.2008.00259.x|anchor=3e046400}}. ====Standardized extracts (capsules and tablets)==== Commercial kava supplements typically contain acetonic or ethanolic extracts standardized to 30–70% kavalactones. Clinical trials have most commonly used doses of 120–240 mg kavalactones per day{{cite|doi=10.1177/0004867419891246|anchor=454f95fc}}. Onset is 30–60 minutes; duration extends to 4–8 hours. The effect profile emphasizes sustained [[effect:anxiety-suppression|anxiolysis]] over the acute sociable character of aqueous preparations. Organic solvent extracts are more strongly associated with hepatotoxicity [[glossary:case-report|case reports]] than aqueous preparations{{cite|doi=10.3390/ijms17040580|anchor=2ff61ad3}}. ====Kava bar beverages==== Kava bars in the United States and elsewhere{{cite|doi=10.1111/dar.14080|anchor=36c9326e}} typically serve aqueous preparations from noble cultivar root powder, often blended or shaken with water and strained to order. Kavalactone content per serving varies significantly depending on the bar's recipe and root source. The experience profile resembles traditional aqueous preparations — sociable, relaxing, and relatively short-acting. Some establishments also serve concentrated "shots" with higher kavalactone loads per volume. ====Instant and micronized kava==== Dehydrated aqueous extracts or finely milled root powder designed to be stirred directly into water without straining. Kavalactone content per gram is generally higher than traditional grind due to reduced fiber content. Onset and duration approximate traditional aqueous preparations. [[glossary:potency]] varies significantly between products and batches{{cite|doi=10.3390/nu12103044|anchor=aae175cd}}. Per-preparation dose tiers, timelines, and [[glossary:bioavailability]] data are in the Dose · by preparation card on this page.

====Toxicity==== [[glossary:hepatotoxicity]] is the primary [[glossary:toxicity]] concern. Approximately 100 [[glossary:case-report|case reports]] of liver injury have been documented globally, predominantly between 1999 and 2010, associated primarily with commercial organic solvent (acetonic or ethanolic) extracts{{cite|doi=10.3390/ijms17040580|anchor=7e5444f2}}{{cite|doi=10.1111/j.1365-2125.2011.04070.x|anchor=4b151eba}}. Outcomes have ranged from mild hepatic [[glossary:enzyme]] [[glossary:elevation]] to acute liver failure requiring transplantation{{cite|doi=10.1016/j.phymed.2018.08.011|anchor=8e822097}} and death. A critical analysis of 26 suspected cases found firm causality difficult to establish in the majority{{cite|doi=10.1097/MEG.0b013e3283036768|anchor=456443aa}}. Multiple competing '''hepatotoxicity mechanisms''' have been proposed, none definitively established{{cite|doi=10.1021/tx100412m|anchor=79ee3825}}: * '''Flavokavain B''' — [[glossary:cytotoxicity]] via [[glossary:oxidative-stress]] pathways in liver cells; elevated in non-noble cultivars and organic solvent extracts{{cite|pubmed=16608246|anchor=a61fe4e2}} * '''Pipermethystine''' from aerial [[glossary:plant-material]] — mitochondrial apoptosis in hepatocytes at high concentrations{{cite|pubmed=14737001|anchor=1b102631}} * '''Reactive metabolite formation''' — kavalactone glutathione conjugates (mercapturates) detected in human urine{{cite|doi=10.1021/tx100412m|anchor=7d62f81d}} * '''Mold hepatotoxins''' — aflatoxins and ochratoxin A from ''Aspergillus'' [[glossary:contamination]] of poorly stored kava{{cite|doi=10.1002/ptr.3464|anchor=63861db2}}{{cite|doi=10.1002/ptr.4620|anchor=670db5e9}} * '''CYP2D6 poor metabolizer phenotype''' as an idiosyncratic susceptibility factor{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=7cc5b45d}} The [[glossary:hypothesis]] that hepatotoxicity occurred only with organic solvent extracts and not traditional aqueous preparations has been contested by documented liver injury from traditional aqueous kava{{cite|doi=10.1111/j.1708-8305.2008.00259.x|anchor=d2f0b6dd}}{{cite|doi=10.1111/j.1365-2125.2011.04070.x|anchor=8e13efd0}}. The rate with traditional noble cultivar aqueous preparations in Pacific populations nevertheless appears substantially lower. '''Risk factors''' include organic solvent extraction, non-noble cultivars, aerial plant material inclusion, concurrent [[substance:alcohol]] use, concurrent hepatotoxic [[glossary:medication|medications]], [[glossary:poor-metabolizer|CYP2D6 poor metabolizer]] status, mold-contaminated raw material, and pre-existing liver disease{{cite|doi=10.1021/tx100412m|anchor=1d1dce77}}{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=b199b041}}. '''Contaminant and adulterant risk:''' Commercial kava products carry several preparation-specific contamination vectors. Non-noble cultivar substitution — visually undetectable — introduces elevated flavokavain B and dihydromethysticin{{cite|doi=10.1055/s-0030-1250290|anchor=b89bb163}}{{cite|doi=10.1002/ptr.3464|anchor=3dfb6801}}. Aerial plant material contamination introduces pipermethystine, which is minimally present in peeled root{{cite|pubmed=14737001|anchor=4f799c81}}. Mycotoxins (aflatoxins B1, B2, G1, G2, and ochratoxin A) from ''Aspergillus'' mold occur in improperly dried or stored material{{cite|doi=10.1002/ptr.3464|anchor=899bd9a1}}. Labeled kavalactone content frequently diverges from actual content{{cite|doi=10.3390/nu12103044|anchor=f33424f3}}. Heavy metal and pesticide residue data for commercial kava products are lacking{{flag|safety-citation-needed}}. No internationally harmonized quality standard exists; a six-point standardization plan specifying noble cultivars, 5-year harvest age, peeled roots only, aqueous extraction, maximum 250 mg kavalactones/day, and Pan-Pacific quality control has been proposed but not implemented at scale{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=4b8ca2c8}}. '''Kava dermopathy''' — a reversible ichthyosis-like scaly, dry, yellowish skin discoloration — occurs in heavy chronic users{{cite|pubmed=12383029|anchor=fb55bb6c}}{{cite|doi=10.1021/tx100412m|anchor=cf48c6dc}}. It resolves upon [[glossary:dose-reduction]] or cessation. Regular kava use may produce false-positive results on [[substance:amphetamine]] immunoassay urine screens; confirmatory GC-MS testing will be negative{{cite|doi=10.1093/jat/bkaa178|anchor=2261392a}}. ====Psychological Risks==== At therapeutic and moderate doses, [[glossary:adverse-effects]] are mild: gastrointestinal upset, [[effect:headache]], [[effect:dizziness]], and [[glossary:fatigue]] are the most commonly reported in clinical trials{{cite|doi=10.1177/0004867419891246|anchor=48c9c2f7}}. High doses produce significant [[effect:sedation]] and motor [[glossary:impairment]]. Tudei (non-noble) cultivars produce prolonged lethargy and [[effect:nausea]] lasting up to two days — the origin of the name "two-day kava"{{cite|doi=10.3390/nu12103044|anchor=3c903e79}}. Kava is not hallucinogenic at standard doses, and no documented cases of kava-induced [[glossary:psychosis]] were identified in retrieved literature. A medicinal dose of 180 mg kavalactones does not impair simulated driving performance; in contrast, oxazepam 30 mg significantly reduces alertness and slows braking reaction time{{cite|doi=10.1080/15389588.2012.682233|anchor=a013c990}}. ====Tolerance & Dependence==== "Reverse [[glossary:tolerance]]" is described in traditional kava communities: regular users report requiring less kava over time, opposite to typical pharmacological tolerance{{cite|doi=10.3390/nu12103044|anchor=2871c1b5}}. The mechanism is poorly understood. Clinical trials of 8–16 weeks have not required [[glossary:dose-escalation]]{{cite|doi=10.1177/0004867419891246|anchor=d9dbbe61}}. [[glossary:dependence]] risk at therapeutic and moderate doses is considered low; kava is described as non-addictive in clinical literature{{cite|doi=10.1155/2021/6851798|anchor=4bd2cf26}}{{cite|doi=10.3109/00048674.2010.522554|anchor=6153c852}}. Heavy [[glossary:chronic-use]] has, however, been associated with physiological dependence. One severe [[glossary:withdrawal]] case involved a 45-year-old man using both kava and [[substance:kratom]] who presented with [[glossary:hallucination|hallucinations]], [[effect:anxiety]], [[effect:insomnia]], and muscle jerking after abrupt cessation{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=acc8cbec}}. [[substance:phenobarbital]] produced significant improvement; the patient was transitioned to [[substance:diazepam]]. Isolated kava withdrawal contribution cannot be definitively separated from concurrent kratom use. Heavy chronic users considering cessation should taper gradually. Medical supervision is recommended for long-term heavy users, and GABAergic withdrawal protocols (phenobarbital or [[substance_class:chemical/benzodiazepine]] taper) may be indicated in severe cases{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=b67cb461}}. ====Drug Interactions==== '''Benzodiazepines (alprazolam and class):''' Additive GABAergic sedation at distinct [[glossary:receptor-binding]] sites. A documented case of coma followed combined kava and [[substance:alprazolam]] use{{cite|pubmed=8967683|anchor=5f16bd16}}. '''Concurrent use should be avoided.''' '''Alcohol:''' Additive [[glossary:central-nervous-system|CNS]] [[effect:depression]] and possible hepatotoxicity [[glossary:potentiation]]. Early hepatotoxicity case reports involved alcohol co-consumption{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=52642b4b}}{{cite|pubmed=16005588|anchor=76a4e77d}}. '''Other CNS depressants (opioids, sedative antihistamines, antipsychotics):''' Additive or synergistic CNS depression via multiple pathways{{cite|pubmed=12383029|anchor=8a4e38fa}}{{cite|doi=10.3109/00048674.2010.522554|anchor=bd7b18c8}}. '''CYP2C9/CYP2C19 substrates (warfarin, phenytoin, omeprazole):''' [[glossary:in-vitro]] [[glossary:inhibition]] demonstrated at kavalactone concentrations of 5–10 µM{{cite|pubmed=16033948|anchor=5039d857}}. No controlled human [[glossary:interaction-study]] confirms clinical significance at standard doses{{flag|citation-needed}}. '''Hepatotoxic medications:''' Additive hepatotoxicity risk on mechanistic grounds. Concurrent use is contraindicated with pre-existing liver disease. '''CYP3A4 substrates (midazolam, immunosuppressants, statins):''' Intestinal CYP3A inhibition demonstrated in [[glossary:animal-model|animal models]]{{cite|doi=10.1055/a-2360-4808|anchor=a153a86d}} but not confirmed at standard doses in humans{{cite|pubmed=17495878|anchor=50117217}}. ====Contraindications==== '''Pre-existing liver disease:''' Absolute [[glossary:contraindication]] given documented hepatotoxicity risk across preparation types{{cite|doi=10.3390/ijms17040580|anchor=d7451173}}. '''Concurrent heavy alcohol use:''' Absolute contraindication — additive hepatotoxicity and CNS depression{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=b1731347}}{{cite|pubmed=16005588|anchor=9b9f0cad}}. '''Concurrent benzodiazepine or GABAergic sedative use:''' Potentially life-threatening interaction documented{{cite|pubmed=8967683|anchor=ddefceda}}. '''Pregnancy and lactation:''' Contraindicated due to insufficient safety data; kavalactones may cross the placenta based on molecular properties{{cite|pubmed=12383029|anchor=f433622c}}{{flag|safety-citation-needed}}. '''Children and adolescents:''' No safety or [[glossary:efficacy]] data exist in pediatric populations. '''CYP2D6 poor metabolizers:''' Potentially increased hepatotoxicity susceptibility{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=f888b73d}}. Caution is advised for users taking narrow [[glossary:therapeutic-index]] medications metabolized by [[glossary:cyp2c9]] or [[glossary:cyp2c19]] (e.g., warfarin, phenytoin), though interaction data are limited to in vitro findings{{cite|pubmed=16033948|anchor=2938b573}}.

====Toxicity==== [[glossary:hepatotoxicity]] is the primary concern. Approximately 100 liver injury cases have been documented globally, predominantly between 1999 and 2010, most linked to organic solvent (acetonic or ethanolic) extracts{{cite|doi=10.3390/ijms17040580|anchor=6919f629}}{{cite|doi=10.1111/j.1365-2125.2011.04070.x|anchor=4d2bb9ec}}. Outcomes have ranged from mild [[glossary:enzyme]] [[glossary:elevation]] to acute liver failure requiring transplantation{{cite|doi=10.1016/j.phymed.2018.08.011|anchor=ac274a56}} and death. Multiple '''hepatotoxicity mechanisms''' have been proposed and none definitively established{{cite|doi=10.1021/tx100412m|anchor=7c15bf77}}: * '''Flavokavain B''' — damages liver cells via [[glossary:oxidative-stress]]; elevated in non-noble cultivars and organic solvent extracts{{cite|pubmed=16608246|anchor=37ef4ab7}} * '''Pipermethystine''' from leaves and stems — [[glossary:trigger|triggers]] mitochondrial [[glossary:cell-death]] in liver models at high concentrations{{cite|pubmed=14737001|anchor=5461cb29}} * '''Reactive metabolites''' — kavalactone breakdown products detected in human urine{{cite|doi=10.1021/tx100412m|anchor=86b6ab33}} * '''Mold toxins''' — aflatoxins and ochratoxin A from ''Aspergillus'' [[glossary:contamination]] of poorly stored kava{{cite|doi=10.1002/ptr.3464|anchor=38b1f2dd}}{{cite|doi=10.1002/ptr.4620|anchor=7ab19a7c}} * '''CYP2D6 poor metabolizers''' — a genetic variation that may increase individual susceptibility{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=25341bfa}} The claim that hepatotoxicity occurs only with organic solvent extracts has been contested — liver injury from traditional aqueous kava has also been documented{{cite|doi=10.1111/j.1708-8305.2008.00259.x|anchor=187a8d4e}}{{cite|doi=10.1111/j.1365-2125.2011.04070.x|anchor=f9b8a770}}. Known risk factors include organic solvent extraction, non-noble cultivars, aerial [[glossary:plant-material]], concurrent [[substance:alcohol]] use, hepatotoxic [[glossary:medication|medications]], [[glossary:poor-metabolizer|CYP2D6 poor metabolizer]] status, mold-contaminated raw material, and pre-existing liver disease{{cite|doi=10.1021/tx100412m|anchor=f41f0bcf}}{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=46f2e842}}. Commercial kava products carry several contamination risks. Non-noble cultivar substitution is visually undetectable and introduces elevated flavokavain B{{cite|doi=10.1055/s-0030-1250290|anchor=f7ea3328}}{{cite|doi=10.1002/ptr.3464|anchor=686de3f5}}. Aerial plant material contamination introduces pipermethystine{{cite|pubmed=14737001|anchor=783df85c}}. Mycotoxins from mold occur in improperly stored material{{cite|doi=10.1002/ptr.3464|anchor=b23b5408}}. Labeled kavalactone content frequently diverges from actual content{{cite|doi=10.3390/nu12103044|anchor=c6aaed75}}.{{flag|safety-citation-needed}} No international quality standard exists; a proposed six-point plan specifying noble cultivars, 5-year harvest age, peeled roots only, aqueous extraction, and a 250 mg/day maximum has not been implemented at scale{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=d17ed8b0}}. '''Kava dermopathy''' — a reversible scaly, yellowish skin discoloration — occurs in heavy chronic users{{cite|pubmed=12383029|anchor=9635affc}}{{cite|doi=10.1021/tx100412m|anchor=8b469991}}. It resolves when use stops or decreases. Regular kava use may trigger false-positive results on [[substance:amphetamine]] urine screens; confirmatory GC-MS testing will be negative{{cite|doi=10.1093/jat/bkaa178|anchor=5cde0883}}. ====Psychological Risks==== At therapeutic and moderate doses, [[glossary:adverse-effects]] are mild: [[effect:nausea]], [[effect:headache]], [[effect:dizziness]], and [[glossary:fatigue]] are the most commonly reported in clinical trials{{cite|doi=10.1177/0004867419891246|anchor=48c174e7}}. High doses produce significant [[effect:sedation]] and motor [[glossary:impairment]]. Tudei (non-noble) cultivars produce prolonged lethargy and nausea lasting up to two days{{cite|doi=10.3390/nu12103044|anchor=8f65ce57}}. Kava is not hallucinogenic at standard doses; a medicinal dose of 180 mg kavalactones does not impair simulated driving — in contrast, oxazepam 30 mg significantly slows braking reaction time{{cite|doi=10.1080/15389588.2012.682233|anchor=f19a8b03}}. ====Tolerance & Dependence==== [[glossary:dependence]] risk at therapeutic and moderate doses is low{{cite|doi=10.1155/2021/6851798|anchor=55d1a909}}{{cite|doi=10.3109/00048674.2010.522554|anchor=bb7a99b2}}. Traditional communities describe "reverse [[glossary:tolerance]]" — regular users needing less kava over time, opposite to typical pharmacological tolerance{{cite|doi=10.3390/nu12103044|anchor=fdc0ea6e}}. Heavy [[glossary:chronic-use]] can produce physiological dependence. One severe case documented a 45-year-old man using kava and [[substance:kratom]] who developed [[glossary:hallucination|hallucinations]], [[effect:anxiety]], [[effect:insomnia]], and muscle jerking after abrupt cessation{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=1bb21c9b}}; [[substance:phenobarbital]] improved symptoms and he transitioned to a [[substance:diazepam]] taper. Clinical trials of 8–16 weeks have not required [[glossary:dose-escalation]]{{cite|doi=10.1177/0004867419891246|anchor=53f05474}}. Heavy chronic users considering cessation should taper gradually. Medical supervision is recommended, and GABAergic [[glossary:withdrawal]] protocols (phenobarbital or [[substance_class:chemical/benzodiazepine]] taper) may be indicated in severe cases{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=865188f9}}. ====Drug Interactions==== '''Benzodiazepines (alprazolam and class):''' Both substances amplify [[glossary:gaba]] signaling through distinct but additive pathways. A documented case of coma followed combined kava and [[substance:alprazolam]] use{{cite|pubmed=8967683|anchor=17c9140b}}. '''Concurrent use should be avoided.''' '''Alcohol:''' Additive sedation and possible additive liver toxicity. Early hepatotoxicity cases involved alcohol co-consumption{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=995628d7}}{{cite|pubmed=16005588|anchor=62d485ae}}. '''Other CNS depressants (opioids, sedative antihistamines, antipsychotics):''' Multiple sedation pathways converge, increasing over-sedation risk{{cite|pubmed=12383029|anchor=2207e515}}{{cite|doi=10.3109/00048674.2010.522554|anchor=42ec0c52}}. '''Warfarin, phenytoin, omeprazole (CYP2C9/CYP2C19 substrates):''' Kavalactones inhibit the enzymes that break down these drugs in laboratory studies at concentrations of 5–10 µM{{cite|pubmed=16033948|anchor=ea5b0307}}. Clinical significance at standard kava doses has not been confirmed in humans.{{flag|citation-needed}} '''Hepatotoxic medications:''' Concurrent use adds to liver stress on mechanistic grounds. Contraindicated with pre-existing liver disease. '''Midazolam, immunosuppressants, statins (CYP3A4 substrates):''' Intestinal enzyme [[glossary:inhibition]] shown in [[glossary:animal-model|animal models]]{{cite|doi=10.1055/a-2360-4808|anchor=ab1baa72}} but not confirmed at standard doses in humans{{cite|pubmed=17495878|anchor=386dc35e}}. ====Contraindications==== Pre-existing liver disease is an absolute [[glossary:contraindication]] given documented hepatotoxicity risk across preparation types{{cite|doi=10.3390/ijms17040580|anchor=117b94e5}}. Concurrent heavy alcohol use is absolutely contraindicated — additive liver and [[glossary:central-nervous-system|CNS]] [[glossary:toxicity]]{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=92220935}}{{cite|pubmed=16005588|anchor=f9610583}}. Concurrent benzodiazepine or GABAergic sedative use carries potentially life-threatening [[glossary:drug-interaction|interaction risk]]{{cite|pubmed=8967683|anchor=87ee1a76}}. Kava is contraindicated in [[glossary:pregnancy]] and lactation due to insufficient safety data{{cite|pubmed=12383029|anchor=b693d4ee}}{{flag|safety-citation-needed}}. No safety or [[glossary:efficacy]] data exist in children or adolescents. CYP2D6 poor metabolizers may face increased hepatotoxicity susceptibility{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=ac50cd7a}}. Caution is warranted for users of narrow [[glossary:therapeutic-index]] medications metabolized by [[glossary:cyp2c9]] or [[glossary:cyp2c19]], such as warfarin or phenytoin, though interaction data are limited to laboratory findings{{cite|pubmed=16033948|anchor=75aa1678}}.

===Forms & Identification=== Kava products range from traditional ground root to standardized capsules, instant powders, and concentrated liquid extracts. Quality varies enormously: labeled kavalactone content frequently diverges from actual content, and noble/tudei cultivar substitution is visually undetectable. A Certificate of Analysis (CoA) from an ISO-accredited laboratory is the most reliable verification — it should confirm kavalactone content, cultivar identity (chemotype analysis showing noble-type kavalactone ratios), absence of elevated flavokavain B, and negative mycotoxin screening. Products without third-party testing carry unquantifiable [[glossary:contamination]] risk. ===Set & Setting=== Kava is traditionally consumed in communal settings, and the sociable character of noble cultivar preparations complements group contexts. First-time users should try kava in a calm, familiar environment with experienced companions. Effects can feel subtle on initial use due to "reverse [[glossary:tolerance]]" — [[glossary:sensitivity]] typically increases over sessions, not decreases. Avoid kava before driving or operating machinery, particularly with unfamiliar products or doses. [[glossary:daily-use]] patterns should be approached with caution despite kava's low [[glossary:dependence]] profile at moderate doses. ===Guidelines=== {{Guideline}} * Start with a single shell (100–150 mL) of traditional aqueous preparation or the lowest recommended dose of a standardized product and wait 30–45 minutes before additional servings * Use only products confirmed as noble cultivar — tudei (non-noble) varieties produce heavier [[effect:sedation]], [[effect:nausea]], and next-day lethargy lasting up to two days * Do not combine kava with [[substance:alcohol]], [[substance_class:chemical/benzodiazepine|benzodiazepines]], [[substance_class:psychoactive/opioid|opioids]], or other [[glossary:cns-depressants]] * If using capsules or extracts, do not exceed 250 mg total kavalactones per day without medical guidance * Monitor for signs of liver stress (dark urine, yellowing skin or eyes, unusual [[glossary:fatigue]], upper right abdominal pain) — discontinue immediately and seek medical evaluation if these appear * Maintain kava-free days each week to reduce cumulative hepatic exposure * Stay hydrated — kava has mild diuretic properties {{/Guideline}} ===Emergency Response=== {{Emergency}} Kava emergencies are rare at standard doses but can occur with very high doses, tudei cultivar [[glossary:ingestion]], or dangerous combinations. '''Recognizing an emergency:''' * Severe sedation or unresponsiveness after kava combined with benzodiazepines, alcohol, or opioids * Signs of acute liver injury: sudden jaundice, severe abdominal pain, dark urine, [[effect:confusion]] * Severe persistent [[effect:vomiting]] preventing fluid intake '''Immediate steps:''' * 1. Do not leave the person alone * 2. Place an unresponsive person in the [[glossary:recovery-position]] * 3. Call emergency services if the person is unresponsive, has difficulty breathing, or shows signs of liver [[glossary:distress]] * 4. Do not attempt to induce vomiting '''What to tell the dispatcher:''' Name the substance (kava), approximate amount consumed, time of ingestion, any other substances taken, and current symptoms. [[glossary:good-samaritan-law|Good Samaritan laws]] exist in many jurisdictions and protect callers reporting drug-related emergencies. No specific reversal agent exists for kava. Supportive care is the standard treatment. {{/Emergency}} ===Aftercare & Integration=== {{Aftercare}} Post-session grogginess is common after moderate-to-heavy kava use, particularly with standardized extracts or high-dose sessions. Hydrate thoroughly before sleep and upon waking. Mild next-day fatigue is normal and typically resolves within hours. If tudei cultivar kava was consumed (intentionally or accidentally), residual sedation and nausea may persist for 24–48 hours — rest and [[glossary:hydration]] are the primary management. Regular users should schedule periodic liver function tests (ALT, AST, GGT) with a healthcare provider, particularly if consuming kava more than three times per week. {{/Aftercare}} ===Recovery & Support=== {{Recovery}} Kava dependence is uncommon at therapeutic doses but can develop with heavy [[glossary:chronic-use]]. Abrupt cessation after sustained heavy use may produce a GABAergic [[glossary:withdrawal]] — [[effect:anxiety]], [[effect:insomnia]], [[glossary:tremor]], and in rare cases [[glossary:hallucination|hallucinations]]{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=99d09f04}}. '''Tapering:''' Reduce intake gradually over 2–4 weeks rather than stopping abruptly. Cut each week's dose by approximately 25%. '''Medical support:''' Heavy chronic users experiencing withdrawal symptoms should seek medical evaluation. GABAergic withdrawal protocols ([[substance:phenobarbital]] or benzodiazepine taper) may be required in severe cases{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=91a1b37f}}. '''Resources:''' * SAMHSA National Helpline (US): 1-800-662-4357 (free, confidential, 24/7) * Alcohol and Drug Foundation (Australia): 1300 85 85 84 * FRANK (UK): 0300 123 6600 {{/Recovery}}

===Forms & Identification=== Kava products range from traditional ground root to standardized capsules, instant powders, and concentrated liquid extracts. Quality varies enormously: labeled kavalactone content frequently diverges from actual content, and noble/tudei cultivar substitution is visually undetectable. Obtain a Certificate of Analysis (CoA) from an ISO-accredited laboratory before using any commercial kava product. The CoA should confirm kavalactone content, noble-type chemotype (kavalactone ratios), absence of elevated flavokavain B, and negative mycotoxin screening. Products without third-party testing carry unquantifiable [[glossary:contamination]] risk. ===Set & Setting=== Kava is traditionally consumed communally, and its prosocial character suits group settings. First-time users often feel little on initial sessions — "reverse [[glossary:tolerance]]" means [[glossary:sensitivity]] typically builds over multiple uses rather than decreasing. Avoid kava before driving or operating machinery, particularly with unfamiliar products or doses. Approach [[glossary:daily-use]] with caution despite kava's low [[glossary:dependence]] profile at moderate doses. ===Guidelines=== {{Guideline}} * Start with a single shell (100–150 mL) of traditional aqueous preparation or the lowest recommended dose of a standardized product and wait 30–45 minutes before additional servings * Use only products confirmed as noble cultivar — tudei (non-noble) varieties produce heavier [[effect:sedation]], [[effect:nausea]], and next-day lethargy lasting up to two days * Do not combine kava with [[substance:alcohol]], [[substance_class:chemical/benzodiazepine|benzodiazepines]], [[substance_class:psychoactive/opioid|opioids]], or other [[glossary:cns-depressants]] * If using capsules or extracts, do not exceed 250 mg total kavalactones per day without medical guidance * Monitor for signs of liver stress (dark urine, yellowing skin or eyes, unusual [[glossary:fatigue]], upper right abdominal pain) — discontinue immediately and seek medical evaluation if these appear * Maintain kava-free days each week to reduce cumulative hepatic exposure * Stay hydrated — kava has mild diuretic properties {{/Guideline}} ===Emergency Response=== {{Emergency}} Kava emergencies are rare at standard doses but can occur with very high doses, tudei cultivar [[glossary:ingestion]], or dangerous combinations. '''Recognizing an emergency:''' * Severe sedation or unresponsiveness after kava combined with benzodiazepines, alcohol, or opioids * Signs of acute liver injury: sudden jaundice, severe abdominal pain, dark urine, [[effect:confusion]] * Severe persistent [[effect:vomiting]] preventing fluid intake '''Immediate steps:''' * 1. Do not leave the person alone * 2. Place an unresponsive person in the [[glossary:recovery-position]] * 3. Call emergency services if the person is unresponsive, has difficulty breathing, or shows signs of liver [[glossary:distress]] * 4. Do not attempt to induce vomiting '''What to tell the dispatcher:''' Name the substance (kava), approximate amount consumed, time of ingestion, any other substances taken, and current symptoms. [[glossary:good-samaritan-law|Good Samaritan laws]] exist in many jurisdictions and protect callers reporting drug-related emergencies. No specific reversal agent exists for kava. Supportive care is the standard treatment. {{/Emergency}} ===Aftercare & Integration=== {{Aftercare}} Post-session grogginess is common after moderate-to-heavy kava use, particularly with standardized extracts or high-dose sessions. Hydrate thoroughly before sleep and upon waking. Mild next-day fatigue is normal and typically resolves within hours. If tudei cultivar kava was consumed — intentionally or accidentally — residual sedation and nausea may persist for 24–48 hours. Rest and [[glossary:hydration]] are the primary management. Regular users should schedule periodic liver function tests (ALT, AST, GGT) with a healthcare provider, particularly if consuming kava more than three times per week. {{/Aftercare}} ===Recovery & Support=== {{Recovery}} Kava dependence is uncommon at therapeutic doses but can develop with heavy [[glossary:chronic-use]]. Abrupt cessation after sustained heavy use may produce a GABAergic [[glossary:withdrawal]] — [[effect:anxiety]], [[effect:insomnia]], [[glossary:tremor]], and in rare cases [[glossary:hallucination|hallucinations]]{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=3361214a}}. '''Tapering:''' Reduce intake gradually over 2–4 weeks rather than stopping abruptly. Cut each week's dose by approximately 25%. '''Medical support:''' Heavy chronic users experiencing withdrawal symptoms should seek medical evaluation. GABAergic withdrawal protocols ([[substance:phenobarbital]] or benzodiazepine taper) may be required in severe cases{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=9f3a9503}}. '''Resources:''' * SAMHSA National Helpline (US): 1-800-662-4357 (free, confidential, 24/7) * Alcohol and Drug Foundation (Australia): 1300 85 85 84 * FRANK (UK): 0300 123 6600 {{/Recovery}}

Kava is [[glossary:unscheduled|not scheduled]] under any of the three principal United Nations [[glossary:drug-control|drug control conventions]]{{cite|name=dea-kava-info|type=web|year=2023|title=DEA Drug and Chemical Information Kava|anchor=35cecade}}. Legal status varies significantly by country. In the United States, kava is sold as a dietary supplement and is not a controlled substance, with a growing kava bar industry across Florida and Pacific coast states{{cite|name=dea-kava-info|type=web|year=2023|title=DEA Drug and Chemical Information Kava|anchor=c56e511c}}. Germany definitively lifted a long-standing ban on June 18, 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=7cb6427a}}{{cite|doi=10.1055/s-0035-1558295|anchor=b1e96121}}. France and the United Kingdom maintain outright bans{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=665263bd}}. Australia permits kava as an over-the-counter listed medicine with a 250 mg/day kavalactone maximum{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=57cfa69c}}. Canada allows it in some natural health product formulations{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=e105436b}}. Pacific Island nations treat kava as a legal cultural and commercial commodity; Vanuatu's Kava Act governs noble cultivar export standards{{cite|doi=10.1111/dar.14080|anchor=e2ba71b4}}. Kavalactones are not individually scheduled in any jurisdiction. {{Warning}} Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information. {{/Warning}} {{flag|citation-needed}} Legal status in [[glossary:member-state|EU member states]] other than Germany and France, South American countries, and Southeast Asian non-producing countries has not been verified in retrieved literature.

Kava and its active kavalactones are [[glossary:unscheduled|not scheduled]] under any of the three principal United Nations [[glossary:drug-control|drug control conventions]]: the 1961 Single Convention on Narcotic Drugs, the 1971 [[glossary:convention-on-psychotropic-substances]], or the 1988 Convention Against Illicit Traffic{{cite|name=dea-kava-info|type=web|year=2023|title=DEA Drug and Chemical Information Kava|anchor=15556088}}. No international treaty restriction applies to kava trade or consumption. Legal status varies significantly by jurisdiction, shaped primarily by national regulatory responses to [[glossary:hepatotoxicity]] [[glossary:case-report|case reports]] in the early 2000s. Several countries maintain outright bans, others restrict kava to regulated health products, and Pacific Island nations treat it as a legal cultural and commercial commodity.

Jurisdiction	Status	Notes
United States (federal)	Not a controlled substance	Sold as a dietary supplement under DSHEA (1994). FDA consumer advisory on hepatotoxicity risk issued 2002. Growing kava bar industry in Florida, California, and Pacific coast states{{cite|name=dea-kava-info|type=web|year=2023|title=DEA Drug and Chemical Information Kava|anchor=266fbbcd}}
Germany	Ban lifted (2024)	BfArM banned kava pharmaceuticals in 2002. Courts overturned the ban beginning circa 2013–2015{{cite|doi=10.1055/s-0035-1558295|anchor=262b5d86}}. Cologne Administrative Court lifted the ban definitively on June 18, 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=e01f0b1f}}
France	Banned	Outright ban maintained as of 2024, with limited exceptions for certain homeopathic preparations{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=ce83b8c5}}
United Kingdom	Banned	No reclassification as of 2025{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=967d4922}}
Australia	Listed medicine (OTC)	TGA approved: maximum 125 mg kavalactones per solid dose, 250 mg/day maximum. Traditional import permitted for Pacific Island communities{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=f4003116}}
Canada	Restricted	Available in some natural health product formulations under NHP regulations{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=39371003}}
Netherlands, Indonesia, Japan, South Korea	Prohibited in supplements	Banned for sale as dietary supplements{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=ec2a3fae}}
Pacific Island nations	Legal	Legal for traditional, cultural, and commercial use. Vanuatu Kava Act 2002 governs noble cultivar export standards. Significant export commodity for Vanuatu, Fiji, and Tonga{{cite|doi=10.1111/dar.14080|anchor=1ed56750}}

Kavalactones are not individually scheduled in any jurisdiction. Unlike some plant preparations where active compounds are [[glossary:international-control|internationally controlled]] (e.g., [[substance:dmt]] in [[substance:ayahuasca]]), kava faces no [[glossary:structural-analog]]-law or constituent scheduling complications. {{flag|citation-needed}} Legal status in [[glossary:member-state|EU member states]] other than Germany and France, South American countries, and Southeast Asian non-producing countries has not been verified in retrieved literature.

Kava's [[substance_class:psychoactive/anxiolytic]] profile results from a polypharmacological mechanism: direct [[glossary:gaba-a-receptor]] [[glossary:potentiation]], [[glossary:channel|ion channel]] [[glossary:blockade]] reducing [[glossary:excitability|neuronal excitability]], [[glossary:nmda-receptor]] [[glossary:antagonism]], and monoaminergic [[glossary:modulation]]. This multi-target activity may explain both clinical [[glossary:efficacy]] and the lack of complete [[glossary:cross-tolerance]] with [[substance_class:chemical/benzodiazepine|benzodiazepines]]. ===GABAA receptor potentiation=== Kavain directly and positively modulates GABAA receptors across multiple [[glossary:subunit]] combinations, with greater potentiation at extrasynaptic α4β2δ [[glossary:receptor|receptors]] than at synaptic α1β2γ2L receptors{{cite|doi=10.1371/journal.pone.0157700|anchor=42822ade}}. This effect is '''not''' blocked by flumazenil, confirming that kavalactones do not act at the classical benzodiazepine [[glossary:binding-site]]. The β3N265M point mutation — known to reduce [[glossary:sensitivity]] to general anesthetics — also diminishes kavain potentiation, suggesting a shared binding region with anesthetic agents{{cite|doi=10.1371/journal.pone.0157700|anchor=26489029}}. Neuroimaging data from an 8-week [[glossary:randomized-controlled-trial]] in generalized [[effect:anxiety]] [[glossary:disorder]] demonstrated decreased [[glossary:gaba]] levels in the dorsal anterior cingulate [[glossary:cortex]] (dACC) following kava treatment (120 mg kavalactones twice daily), measured by proton magnetic resonance spectroscopy (1H-MRS){{cite|doi=10.3390/nu15214586|anchor=ee81b28a}}. Peripheral gene [[glossary:expression]] analysis from the same trial revealed decreased GABRR2 (GABAA rho subunit) expression{{cite|doi=10.1002/ptr.7999|anchor=e5da4ded}}. ===Ion channel and glutamate modulation=== Kavalactones block voltage-gated sodium channels, reducing neuronal excitability and underlying both local anesthetic and anticonvulsant properties{{cite|pubmed=12383029|anchor=cc798ea5}}. Dihydromethysticin and kavain reversibly reduce NMDA-receptor- and calcium-channel-mediated field potentials in guinea pig [[glossary:hippocampus|hippocampal]] CA1/CA3 regions at 5–40 µmol/L, with [[glossary:additive-effects]] when combined{{cite|pubmed=9194150|anchor=9212d268}}. The serotonergic system may also be involved: additive effects have been observed with the [[substance_class:pharmacological/serotonin-1a-receptor-agonist|serotonin 1A receptor agonist]] ipsapirone in hippocampal slice preparations{{cite|pubmed=9194150|anchor=dc69f5bc}}. ===Monoaminergic modulation=== Kavalactones reversibly inhibit [[glossary:mao-b]] (MAO-B), contributing to elevated [[glossary:dopamine]] and phenylethylamine levels{{cite|doi=10.3109/00048674.2010.522554|anchor=fc8157c0}}. [[glossary:norepinephrine|Noradrenaline]] and [[substance_class:pharmacological/dopamine-reuptake-inhibitor]] has been documented for several kavalactones{{cite|doi=10.3109/00048674.2010.522554|anchor=37717b93}}. ===Pharmacokinetics=== The first clinical pharmacokinetic study of kavalactones in healthy volunteers established a tmax of 1–3 hours across major kavalactones after oral dosing{{cite|doi=10.1016/j.jep.2022.115514|anchor=772b5c47}}. Despite kavain comprising approximately 44% of extract content, dihydrokavain achieves the highest [[glossary:plasma]] cmax (173.5 ± 173.1 ng/mL), followed by kavain (112.0 ± 117.2 ng/mL) and dihydromethysticin (92.9 ± 73.4 ng/mL){{cite|doi=10.1016/j.jep.2022.115514|anchor=1c4b6411}}. [[glossary:half-life|Elimination half-life]] is approximately 9 hours for kavalactones and their [[glossary:metabolite|metabolites]]. Urinary [[glossary:excretion]] accounts for more than 90% of kawain [[glossary:elimination]] within 72 hours{{cite|pubmed=16033948|anchor=9d63d5a7}}. Oral [[glossary:bioavailability]] has not been formally quantified in humans; in a rat model, kava extract co-administration tripled kawain AUC through self-[[glossary:inhibition]] of CYP [[glossary:metabolism]]{{cite|pubmed=16033948|anchor=560dd4af}}. Kavalactone metabolites identified in human urine include mercapturates (glutathione conjugates), indicating reactive metabolite formation [[glossary:in-vivo|in vivo]]{{cite|doi=10.1021/tx100412m|anchor=62d7b699}}. ===CYP enzyme interactions=== [[glossary:in-vitro]], kava extract and individual kavalactones inhibit [[glossary:cyp2c9]], [[glossary:cyp2c19]], [[glossary:cyp2d6]], and [[glossary:cyp3a4]], with [[glossary:ki|Ki values]] of 5–10 µM for methysticin, dihydromethysticin, and desmethoxyyangonin at CYP2C9 and CYP2C19{{cite|pubmed=16033948|anchor=0332ca1d}}. In vivo human studies at standard supplemental doses (14-day supplementation), however, showed no significant inhibition of CYP3A4{{cite|pubmed=17495878|anchor=d79478a2}}, CYP2D6{{cite|doi=10.1002/mnfr.200600300|anchor=78615810}}, or P-glycoprotein-mediated transport{{cite|pubmed=17079360|anchor=aa6f383b}}. Multiple CYP isoforms (1A2, 2D6, 2E1, 3A4/5) were assessed without clinically significant findings{{cite|pubmed=15900287|anchor=03b93d30}}. In rats, kava extract increased [[substance:midazolam]] cmax and AUC approximately 4-fold via intestinal CYP3A inhibition, and increased P-glycoprotein [[glossary:substrate]] fexofenadine [[glossary:reuptake|uptake]] 3.5-fold{{cite|doi=10.1055/a-2360-4808|anchor=006bcc10}}. This discrepancy between in vitro [[glossary:potency]] and in vivo clinical irrelevance at standard doses suggests that inhibitory kavalactone concentrations may not be achieved systemically, though intestinal CYP3A inhibition at higher doses remains plausible. ===Open questions=== Three preparation-specific puzzles remain unresolved. First, the mechanism of "reverse [[glossary:tolerance]]" — the widely reported phenomenon of regular users requiring less kava over time — has no established pharmacological explanation and runs counter to typical receptor-mediated tolerance. Second, no formal human oral bioavailability study has been published for any individual kavalactone. Third, the relative contributions of individual kavalactones versus their combined action (possible synergy or antagonism within the extract matrix) to the overall anxiolytic effect remain uncharacterized in controlled human studies.

Kava's experiential character is shaped more by preparation and cultivar than by dose alone. Traditional aqueous beverages from noble cultivars produce a distinctively clear-headed [[glossary:sociability]] with prominent [[effect:muscle-relaxation]] and perioral numbness — a combination that users often describe as relaxing without sedating at moderate intake. Standardized pharmaceutical extracts, by contrast, emphasize sustained [[effect:anxiety-suppression|anxiolysis]] with less of the acute sociable quality. Tudei (non-noble) cultivars produce a qualitatively different, heavier experience dominated by [[effect:sedation]], [[effect:nausea]], and residual lethargy. [[glossary:set-and-setting]] interact substantially with these preparation differences: the communal context of traditional ceremony amplifies the sociable and prosocial dimensions. Pharmacologically, kava occupies a position between [[substance_class:chemical/benzodiazepine|benzodiazepines]] and [[substance:alcohol]] as a GABAergic [[substance_class:psychoactive/anxiolytic]], but with notable divergences: it does not produce the [[effect:cognitive-impairment]] or amnestic effects characteristic of benzodiazepines at therapeutic doses, and it does not impair driving performance at clinical doses where oxazepam does. Compared to alcohol, kava produces muscle relaxation and anxiolysis without the [[effect:disinhibition]]-driven behavioral escalation or next-day hangover typical of ethanol — though non-noble cultivars partially erode this advantage.

===Toxicity=== No human [[glossary:lethal-dose|LD50]] data have been published for kava or individual kavalactones. The toxicological profile is based on approximately 100 [[glossary:case-report|case reports]] of liver injury documented globally, predominantly between 1999 and 2010, associated primarily with commercial organic solvent (acetonic or ethanolic) extracts{{cite|doi=10.3390/ijms17040580|anchor=d855e657}}{{cite|doi=10.1111/j.1365-2125.2011.04070.x|anchor=4f6aeb20}}. Outcomes range from mild hepatic [[glossary:enzyme]] [[glossary:elevation]] to acute liver failure, liver transplantation{{cite|doi=10.1016/j.phymed.2018.08.011|anchor=8652e9ee}}, and death. A critical analysis of 26 cases suspected by regulatory agencies found firm causality difficult to establish in the majority{{cite|doi=10.1097/MEG.0b013e3283036768|anchor=3f706936}}. Multiple competing '''hepatotoxicity mechanisms''' have been proposed, none definitively established{{cite|doi=10.1021/tx100412m|anchor=ccd18cd0}}{{flag|additional-citations-needed}}: * '''Flavokavain B cytotoxicity''' — GSH-sensitive oxidative stress via IKK/NF-κB and MAPK pathways in HepG2 cells; higher content in non-noble cultivars and organic solvent extracts{{cite|pubmed=16608246|anchor=78cd9597}} * '''Pipermethystine''' from aerial plant material — 90% HepG2 cell death at 100 µM; mitochondrial apoptosis via caspase-3 [[glossary:activation]]{{cite|pubmed=14737001|anchor=b58c2a9e}} * '''Reactive metabolite formation''' — kavalactone glutathione conjugates (mercapturates) detected in human urine; [[glossary:in-vitro|in vitro]] GSH addition reduces cytotoxicity{{cite|doi=10.1021/tx100412m|anchor=b9b9093f}} * '''Mold hepatotoxins''' — aflatoxins and ochratoxin A from ''Aspergillus'' [[glossary:contamination]] of poorly dried kava; background levels detected but direct causal link not established{{cite|doi=10.1002/ptr.3464|anchor=6d4d33c5}}{{cite|doi=10.1002/ptr.4620|anchor=829b04fe}} * '''CYP2D6 poor metabolizer phenotype''' as idiosyncratic susceptibility factor{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=9f61763f}} The "Pacific kava paradox" — the [[glossary:hypothesis]] that hepatotoxicity occurred only with organic solvent extracts, not traditional aqueous preparations — has been contested by documented hepatotoxicity from traditional aqueous kava consumed in a Samoan ceremony{{cite|doi=10.1111/j.1708-8305.2008.00259.x|anchor=cf6b1910}} and in New Caledonia and Australia{{cite|doi=10.1111/j.1365-2125.2011.04070.x|anchor=a4606f4e}}. The rate of hepatotoxicity with traditional noble cultivar aqueous preparations in Pacific populations nevertheless appears substantially lower. '''Risk factors for hepatotoxicity''' include organic solvent extraction, non-noble cultivars, inclusion of aerial plant material (leaves, stem peelings), concurrent [[substance:alcohol]] use, concurrent hepatotoxic [[glossary:medication|medications]], [[glossary:poor-metabolizer|CYP2D6 poor metabolizer]] status, mold-contaminated raw material, and pre-existing liver disease{{cite|doi=10.1021/tx100412m|anchor=3a246786}}{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=0ed02b42}}. ====Contaminant and adulterant risk==== Commercial kava products carry preparation-specific contamination vectors: * '''Aerial plant material contamination:''' Products containing stems, leaves, or peelings introduce pipermethystine, which is minimally present in peeled root and rhizome material{{cite|pubmed=14737001|anchor=d8b1afcf}} * '''Non-noble cultivar substitution:''' Visually indistinguishable from noble cultivars; introduces elevated flavokavain B and dihydromethysticin content{{cite|doi=10.1055/s-0030-1250290|anchor=4cc39aaf}}{{cite|doi=10.1002/ptr.3464|anchor=1a6da323}} * '''Mycotoxin contamination:''' Aflatoxins (B1, B2, G1, G2) and ochratoxin A from ''Aspergillus'' mold in improperly dried or stored raw material; background levels detected in kava samples{{cite|doi=10.1002/ptr.3464|anchor=e674429c}} * '''Kavalactone content variability:''' Commercial products show significant discrepancy between labeled and actual kavalactone content{{cite|doi=10.3390/nu12103044|anchor=69b63186}} * '''Heavy metals and pesticide residues:''' Hypothesized contamination risk in unregulated commercial products; no primary analytical study quantifying heavy metal or pesticide levels in kava products was identified in retrieved literature{{flag|safety-citation-needed}} No internationally harmonized kava product quality standard exists. A six-point standardization plan has been proposed — specifying noble cultivars, 5-year minimum harvest age, peeled roots only, aqueous extraction, maximum 250 mg kavalactones/day, and Pan-Pacific quality control enforcement — but has not been implemented at scale{{cite|doi=10.1016/j.phymed.2010.10.002|anchor=dd864dbf}}{{flag|additional-citations-needed}}. '''Kava dermopathy''' — a reversible ichthyosis-like scaly, dry, yellowish skin discoloration — has been documented in heavy chronic kava users in Pacific Island communities{{cite|pubmed=12383029|anchor=ad49b0b4}}{{cite|doi=10.1021/tx100412m|anchor=f9d0e950}}. The mechanism is unclear; hypotheses include niacin interference and kavalactone reactive [[glossary:metabolite]] binding to skin proteins. The condition reverses upon dose reduction or cessation. Regular kava use may produce false-positive results on [[substance:amphetamine]] immunoassay urine drug screens; confirmatory GC-MS testing will be negative for amphetamines{{cite|doi=10.1093/jat/bkaa178|anchor=b97fc341}}{{flag|additional-citations-needed}}. ===Psychological risks=== At therapeutic and moderate recreational doses, acute [[glossary:adverse-effects]] are mild: gastrointestinal upset, [[effect:headache]], [[effect:dizziness]], and [[glossary:fatigue]] are the most commonly reported in randomized controlled trials{{cite|doi=10.1177/0004867419891246|anchor=e50e812d}}. At high doses, significant [[effect:sedation]] and motor [[glossary:impairment]] may occur. '''Tudei (non-noble) cultivars''' produce prolonged lethargy and [[effect:nausea]] lasting up to two days — the origin of the name "two-day kava"{{cite|doi=10.3390/nu12103044|anchor=af2e100e}}. No documented cases of kava-induced [[glossary:psychosis]] were identified in retrieved literature. Kava is not hallucinogenic at standard doses. A medicinal dose of 180 mg kavalactones does not impair simulated driving performance; in contrast, oxazepam 30 mg significantly reduces alertness and slows braking reaction time{{cite|doi=10.1080/15389588.2012.682233|anchor=cc251378}}{{flag|additional-citations-needed}}. ===Tolerance and dependence=== "Reverse [[glossary:tolerance]]" is described in Pacific Islander kava communities: regular users report requiring less kava over time to achieve desired effects, opposite to typical pharmacological tolerance{{cite|doi=10.3390/nu12103044|anchor=12e1973c}}. The mechanism is poorly understood. In clinical randomized controlled trials of 8–16 weeks duration, [[glossary:dose-escalation]] was not required{{cite|doi=10.1177/0004867419891246|anchor=337c00d5}}. At therapeutic and moderate recreational doses, [[glossary:dependence]] risk is considered low; kava is described as non-addictive in clinical literature{{cite|doi=10.1155/2021/6851798|anchor=195809a1}}{{cite|doi=10.3109/00048674.2010.522554|anchor=df97554f}}. Heavy [[glossary:chronic-use]] in traditional contexts has, however, been associated with physiological dependence. One severe [[glossary:withdrawal]] case has been documented: a 45-year-old man using both kava and [[substance:kratom]] heavily presented to the emergency department with auditory and visual [[glossary:hallucination|hallucinations]], [[effect:anxiety]], [[effect:insomnia]], and diffuse muscle jerking after abrupt cessation{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=9139d0d1}}. [[substance:buprenorphine]] (administered for suspected kratom withdrawal component) was insufficient; [[substance:phenobarbital]] produced significant improvement, and the patient was transitioned to [[substance:diazepam]]. The GABAergic withdrawal pattern is consistent with kava's mechanism of action, though isolated kava contribution cannot be definitively separated from concurrent kratom withdrawal. Heavy chronic users considering cessation should taper gradually rather than discontinue abruptly. Medical supervision is recommended for long-term heavy users, and GABAergic withdrawal protocols (phenobarbital or [[substance_class:chemical/benzodiazepine]]) may be indicated in severe cases{{cite|doi=10.1016/j.ajem.2025.06.016|anchor=dd222af7}}{{flag|additional-citations-needed}}. ===Drug interactions=== Kava's polypharmacology — GABA-A [[glossary:potentiation]], sodium [[glossary:channel]] [[glossary:blockade]], MAO-B [[glossary:inhibition]], and [[glossary:cytochrome-p450|CYP enzyme]] inhibition — creates interaction potential across multiple drug classes. The most clinically significant interactions involve pharmacodynamic synergism with other [[glossary:cns-depressants]] and pharmacokinetic interference with CYP-metabolized medications. '''Benzodiazepines (alprazolam and class):''' Pharmacodynamic synergism via additive GABAergic sedation at distinct [[glossary:receptor-binding]] sites. A documented case of coma followed combined kava and [[substance:alprazolam]] use{{cite|pubmed=8967683|anchor=6b38e6bc}}{{flag|additional-citations-needed}}. '''Concurrent use should be avoided.''' '''Alcohol:''' Additive [[glossary:central-nervous-system|CNS]] [[effect:depression]] and possible pharmacokinetic potentiation of hepatotoxicity. An early kava hepatotoxicity case report involved alcohol co-consumption{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=aaf58f7a}}{{cite|pubmed=16005588|anchor=5d3b8d9f}}. '''Other CNS depressants (opioids, sedative antihistamines, antipsychotics):''' Additive or synergistic CNS depression via multiple pathways. Clinical data beyond the alprazolam case report are limited to mechanistic [[glossary:inference]]{{cite|pubmed=12383029|anchor=9ebe9f0c}}{{cite|doi=10.3109/00048674.2010.522554|anchor=b09e03df}}. '''CYP2C9/CYP2C19 substrates (warfarin, phenytoin, omeprazole):''' In vitro [[glossary:ki|Ki values]] of 5–10 µM for methysticin, dihydromethysticin, and desmethoxyyangonin at CYP2C9 and CYP2C19{{cite|pubmed=16033948|anchor=db508fb6}}{{flag|additional-citations-needed}}. No controlled human pharmacokinetic study or clinical case report confirming this interaction was retrieved. Clinical significance at standard therapeutic doses is uncertain{{flag|citation-needed}}. '''Hepatotoxic medications:''' Additive hepatotoxicity risk on mechanistic grounds. Concurrent use is contraindicated in the presence of pre-existing liver disease. '''CYP3A4 substrates (midazolam, immunosuppressants, statins):''' Intestinal CYP3A inhibition demonstrated in rats (4-fold [[substance:midazolam]] AUC increase){{cite|doi=10.1055/a-2360-4808|anchor=b010e30c}} but not confirmed at standard supplemental doses in humans{{cite|pubmed=17495878|anchor=09998c65}}. Clinical significance at typical medicinal doses is likely low. ===Contraindications=== '''Pre-existing liver disease:''' Absolute [[glossary:contraindication]] given the documented hepatotoxicity risk across preparation types{{cite|doi=10.3390/ijms17040580|anchor=9e6b298d}}{{flag|additional-citations-needed}}. '''Concurrent heavy alcohol use:''' Absolute contraindication — additive hepatotoxicity risk and CNS depression{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=c27192f4}}{{cite|pubmed=16005588|anchor=0af856f5}}. '''Concurrent benzodiazepine or GABAergic sedative use:''' Potentially life-threatening pharmacodynamic interaction documented{{cite|pubmed=8967683|anchor=f33ff62d}}{{flag|additional-citations-needed}}. '''Pregnancy and lactation:''' Contraindicated due to insufficient safety data; kavalactones may cross the placenta based on molecular weight and [[glossary:lipophilicity]]{{cite|pubmed=12383029|anchor=0e58717d}}{{flag|additional-citations-needed}}. No clinical study of kava in [[glossary:pregnancy]] has been published; this contraindication is based on mechanistic concern and the precautionary principle{{flag|safety-citation-needed}}. '''Children and adolescents:''' No safety or [[glossary:efficacy]] data exist in pediatric populations. '''CYP2D6 poor metabolizers:''' Potentially increased susceptibility to hepatotoxicity; [[glossary:cyp2d6]] [[glossary:genetic-polymorphism|polymorphism]] has been identified as a possible risk factor{{cite|doi=10.7326/0003-4819-135-1-200107030-00036|anchor=01ab2ffe}}{{flag|additional-citations-needed}}. Users taking narrow therapeutic index medications metabolized by CYP2C9 or CYP2C19 (e.g., warfarin, phenytoin) should exercise caution, though clinical interaction data remain limited to in vitro findings{{cite|pubmed=16033948|anchor=53a2eac3}}{{flag|additional-citations-needed}}.

Kava (''Piper methysticum'') and kavalactones are [[glossary:unscheduled|not scheduled]] under any of the three principal United Nations [[glossary:drug-control|drug control conventions]]: the 1961 Single Convention on Narcotic Drugs, the 1971 [[glossary:convention-on-psychotropic-substances]], or the 1988 Convention Against Illicit Traffic{{cite|name=dea-kava-info|type=web|year=2023|title=DEA Drug and Chemical Information Kava|anchor=9db43ba1}}. No international treaty restriction applies to kava trade or consumption. Legal status varies significantly by jurisdiction, shaped primarily by national regulatory responses to [[glossary:hepatotoxicity]] [[glossary:case-report|case reports]] in the early 2000s.

Jurisdiction	Classification	Key provisions
United States (federal)	Not a controlled substance	Sold as a dietary supplement under DSHEA (1994). FDA does not classify kava as GRAS; consumer advisory regarding hepatotoxicity risk issued 2002. Growing kava bar industry in Florida, California, and Pacific coast states{{cite|name=dea-kava-info|type=web|year=2023|title=DEA Drug and Chemical Information Kava|anchor=b1b3d6c9}}
Germany	Ban lifted (2024)	BfArM banned kava-containing pharmaceutical products in 2002. Administrative courts began overturning the ban circa 2013–2015{{cite|doi=10.1055/s-0035-1558295|anchor=a9df46b8}}. Cologne Administrative Court definitively lifted the ban on June 18, 2024{{cite|name=german-kava-ruling-2024|type=web|year=2024|title=German Kava Regulatory History Court Ruling June 2024|anchor=e90662b9}}. Products may return under January 2018 marketing authorizations with warning labels
France	Banned	Outright ban on kava in any form maintained as of 2024, with limited exceptions for certain approved homeopathic preparations{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=8342c1db}}
United Kingdom	Banned	No reclassification as of 2025{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=7a897577}}
Australia	Listed medicine (OTC)	TGA approved: maximum 125 mg kavalactones per solid dose form; maximum daily dose 250 mg kavalactones. Traditional kava import permitted for Pacific Island communities{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=4c2a1628}}
Canada	Restricted	Previously restricted; available in some natural health product formulations under NHP regulations{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=b5a1c409}}
Netherlands, Indonesia, Japan, South Korea	Prohibited in supplements	Banned for sale as dietary supplements{{cite|name=kava-legal-overview-2024|type=web|year=2024|title=Kava legal and regulatory status overview 2024-2025|anchor=1aa27c3c}}
Pacific Island nations	Legal	Legal for traditional, cultural, and commercial use. Vanuatu Kava Act 2002 governs noble cultivar standards for export. Kava is a significant export commodity for Vanuatu, Fiji, and Tonga{{cite|doi=10.1111/dar.14080|anchor=82e0022f}}

Kava's active constituents (kavalactones) are not individually scheduled in any jurisdiction. Unlike some plant preparations (e.g., [[substance:ayahuasca]], where the active compound [[substance:dmt]] is internationally scheduled while the [[glossary:plant-material]] is not), kava faces no [[glossary:structural-analog]]-law or treaty-level constituent scheduling complications. {{flag|citation-needed}} Legal status in [[glossary:member-state|EU member states]] other than Germany and France, South American countries, and Southeast Asian non-producing countries has not been verified in retrieved literature.